

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
080 FIBRINOGEN		CLIA TEST ID #: 825	EVALUATION CRITERIA: TARGET VALUE 20 %						
2022-161	73 ACL 8 TO E	87 HEMOSIL-C		10	272.900	11.158	4.09	218.000	327.000
2022-161	79 CS-2500	67 DADE		11	229.182	10.152	4.43	183.000	275.000
2022-162	73 ACL 8 TO E	87 HEMOSIL-C		10	226.700	10.678	4.71	181.000	272.000
2022-162	79 CS-2500	67 DADE		11	172.455	10.378	6.02	138.000	207.000
2022-163	73 ACL 8 TO E	87 HEMOSIL-C		10	523.000	26.378	5.04	418.000	628.000
2022-163	79 CS-2500	67 DADE		11	438.182	18.285	4.17	351.000	526.000
2022-164	73 ACL 8 TO E	87 HEMOSIL-C		10	277.100	14.195	5.12	222.000	333.000
2022-164	79 CS-2500	67 DADE		11	226.455	12.587	5.56	181.000	272.000
2022-165	73 ACL 8 TO E	87 HEMOSIL-C		10	179.500	13.403	7.47	144.000	215.000
2022-165	79 CS-2500	67 DADE		11	136.455	6.472	4.74	109.000	164.000
081 PART.THROM. TIME-PTT		CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-161	62 DADE SYS.	35 DADE ACTIN		55	40.319	2.216	5.50	34.300	46.400
2022-161	65 DADE BFTII	35 DADE ACTIN		12	43.850	4.233	9.65	37.300	50.400
2022-161	69 DIAG.STAGO	49 STA-PTT		17	47.913	2.044	4.27	40.700	55.100
2022-161	73 ACL 8 TO E	56 PTT-HEMO		38	45.534	1.417	3.11	38.700	52.400
2022-161	76 STAGO STAR	49 STA-PTT		25	44.967	2.237	4.98	38.200	51.700
2022-161	79 CS-2500	35 DADE ACTIN		12	42.225	1.990	4.71	35.900	48.600
2022-162	62 DADE SYS.	35 DADE ACTIN		55	23.757	1.010	4.25	20.200	27.300
2022-162	65 DADE BFTII	35 DADE ACTIN		12	23.958	1.807	7.54	20.400	27.600
2022-162	69 DIAG.STAGO	49 STA-PTT		17	26.488	0.774	2.92	22.500	30.500
2022-162	73 ACL 8 TO E	56 PTT-HEMO		38	29.630	0.953	3.22	25.200	34.100
2022-162	76 STAGO STAR	49 STA-PTT		25	25.917	1.201	4.63	22.000	29.800
2022-162	79 CS-2500	35 DADE ACTIN		12	24.350	0.433	1.78	20.700	28.000

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 140 COAGULATION (HEMAT.)

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
081	PART.THROM. TIME-PTT	CLIA TEST ID #: 835	EVALUATION CRITERIA: TARGET VALUE 15 %								
2022-163	62 DADE SYS.	35 DADE ACTIN		55	24.658	0.750	3.04	21.000	28.400		
2022-163	65 DADE BFTII	35 DADE ACTIN		12	24.033	2.075	8.63	20.400	27.600		
2022-163	69 DIAG.STAGO	49 STA-PTT		17	30.869	1.975	6.40	26.200	35.500		
2022-163	73 ACL 8 TO E	56 PTT-HEMO		38	41.984	2.399	5.71	35.700	48.300		
2022-163	76 STAGO STAR	49 STA-PTT		25	28.308	1.668	5.89	24.100	32.600		
2022-163	79 CS-2500	35 DADE ACTIN		12	24.800	0.379	1.53	21.100	28.500		
2022-164	62 DADE SYS.	35 DADE ACTIN		55	33.863	1.665	4.92	28.800	38.900		
2022-164	65 DADE BFTII	35 DADE ACTIN		12	36.342	3.573	9.83	30.900	41.800		
2022-164	69 DIAG.STAGO	49 STA-PTT		17	38.181	1.590	4.16	32.500	43.900		
2022-164	73 ACL 8 TO E	56 PTT-HEMO		38	39.961	1.397	3.50	34.000	46.000		
2022-164	76 STAGO STAR	49 STA-PTT		25	37.550	2.813	7.49	31.900	43.200		
2022-164	79 CS-2500	35 DADE ACTIN		12	35.542	1.092	3.07	30.200	40.900		
2022-165	62 DADE SYS.	35 DADE ACTIN		55	24.667	1.028	4.17	21.000	28.400		
2022-165	65 DADE BFTII	35 DADE ACTIN		12	25.467	1.890	7.42	21.600	29.300		
2022-165	69 DIAG.STAGO	49 STA-PTT		17	30.312	1.562	5.15	25.800	34.900		
2022-165	73 ACL 8 TO E	56 PTT-HEMO		38	31.541	1.092	3.46	26.800	36.300		
2022-165	76 STAGO STAR	49 STA-PTT		25	29.021	2.060	7.10	24.700	33.400		
2022-165	79 CS-2500	35 DADE ACTIN		12	25.733	0.517	2.01	21.900	29.600		
082	PROTHROMBIN TIME(P.T)	CLIA TEST ID #: 845									
2022-161	62 DADE SYS.	33 DADE INNOV		56	26.544	1.259	4.74	22.600	30.500		
2022-161	65 DADE BFTII	33 DADE INNOV		13	29.208	2.248	7.70	24.800	33.600		
2022-161	73 ACL 8 TO E	41 HEMOSIL RE		34	33.788	1.685	4.99	28.700	38.900		
2022-161	76 STAGO STAR	44 STA NEO CI		16	36.894	2.050	5.56	31.400	42.400		
2022-161	79 CS-2500	33 DADE INNOV		13	26.300	0.454	1.73	22.400	30.200		
2022-162	62 DADE SYS.	33 DADE INNOV		56	11.094	0.599	5.40	9.400	12.800		
2022-162	65 DADE BFTII	33 DADE INNOV		13	10.515	0.711	6.76	8.900	12.100		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 140 COAGULATION (HEMAT.)							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-162	73	ACL 8 TO E	41	HEMOSIL RE	34	11.665	0.275	2.36	9.900	13.400	
2022-162	76	STAGO STAR	44	STA NEO CI	16	13.281	0.452	3.40	11.300	15.300	
2022-162	79	CS-2500	33	DADE INNOV	13	11.425	0.060	0.52	9.700	13.100	
082 PROTHROMBIN TIME(PT)			CLIA TEST ID #: 845		EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-163	62	DADE SYS.	33	DADE INNOV	56	11.035	0.302	2.74	9.400	12.700	
2022-163	65	DADE BFTII	33	DADE INNOV	13	10.492	0.708	6.74	8.900	12.100	
2022-163	73	ACL 8 TO E	41	HEMOSIL RE	34	11.829	0.192	1.62	10.100	13.600	
2022-163	76	STAGO STAR	44	STA NEO CI	16	14.094	0.401	2.84	12.000	16.200	
2022-163	79	CS-2500	33	DADE INNOV	13	11.308	0.185	1.63	9.600	13.000	
2022-164	62	DADE SYS.	33	DADE INNOV	56	19.289	0.848	4.40	16.400	22.200	
2022-164	65	DADE BFTII	33	DADE INNOV	13	20.208	1.827	9.04	17.200	23.200	
2022-164	73	ACL 8 TO E	41	HEMOSIL RE	34	23.503	1.130	4.81	20.000	27.000	
2022-164	76	STAGO STAR	44	STA NEO CI	16	26.727	1.198	4.48	22.700	30.700	
2022-164	79	CS-2500	33	DADE INNOV	13	19.600	0.280	1.43	16.700	22.500	
2022-165	62	DADE SYS.	33	DADE INNOV	56	12.278	1.061	8.64	10.400	14.100	
2022-165	65	DADE BFTII	33	DADE INNOV	13	11.746	0.861	7.33	10.000	13.500	
2022-165	73	ACL 8 TO E	41	HEMOSIL RE	34	13.152	0.402	3.05	11.200	15.100	
2022-165	76	STAGO STAR	44	STA NEO CI	16	14.269	0.409	2.87	12.100	16.400	
2022-165	79	CS-2500	33	DADE INNOV	13	12.454	0.231	1.85	10.600	14.300	

SPE: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 100 HEMA. CELL IDENTIFI.							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
072 HEMA. CELL IDENTIFI.											
2022-111					013 013		013 - LYMPHOCYTE	1752	852	1733	100
2022-111					013 013		020 - GIANT PLA	1752	4	1733	0
2022-111					013 013		014 - LYMPHOCYTE	1752	2	1733	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 100 HEMA. CELL IDENTIFI.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-111					008 008		026 - LEUKOCYTE	1752	1	1733	0
2022-111					008 008		006 - SEGMENTED	1752	2	1733	0
2022-111					008 008		007 - BASOPHIL,	1752	5	1733	0
2022-111					013 013		007 - BASOPHIL,	1752	5	1733	0
2022-111					013 013		032 - NUCLEATED	1752	1	1733	0
2022-111					013 013		043 - ECHINOCYTE	1752	1	1733	0
2022-111					013 013		018 - PLATELETS,	1752	3	1733	0
2022-111					008 008		008 - EOSINOPHIL	1752	881	1733	100
072 HEMA. CELL IDENTIFI.											
2022-112					043 043		043 - ECHINOCYTE	887	878	878	100
2022-112					043 043		041 - ACANTHOCYT	887	9	878	0
2022-113					053 053		053 - STOMATOCYT	887	885	885	100
2022-113					053 053		014 - LYMPHOCYTE	887	1	885	0
2022-113					053 053		044 - ERYTHROCYT	887	1	885	0
2022-114					014 014		043 - ECHINOCYTE	887	1	884	0
2022-114					014 014		014 - LYMPHOCYTE	887	884	884	100
2022-114					014 014		001 - BLAST	887	1	884	0
2022-114					014 014		017 - MONOCYTE	887	1	884	0
2022-115					018 018		014 - LYMPHOCYTE	887	1	848	0
2022-115					018 018		018 - PLATELETS,	887	848	848	100
2022-115					018 018		020 - GIANT PLA	887	38	848	0

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 137 RETICULOCYTE COUNT

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
149	RETICULOCYTE COUNT	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{GREATER}				
2022-141	7	M.B.MANUAL			17	1.606	0.686	42.71	0	3.700
2022-141	9	M.B. RICCA			26	1.332	0.332	24.92	0.300	2.300
2022-141	24	Unicel DxH			15	0.567	0.107	18.97	0.200	0.900
2022-141	25	SYSMEX XN			24	0.904	0.110	12.15	0.600	1.200
2022-142	7	M.B.MANUAL			17	5.594	2.244	40.11	0	12.300
2022-142	9	M.B. RICCA			26	4.727	1.372	29.02	0.600	8.800
2022-142	24	Unicel DxH			15	2.587	0.285	11.01	1.700	3.400
2022-142	25	SYSMEX XN			24	1.892	0.330	17.46	0.900	2.900
2022-143	7	M.B.MANUAL			17	1.375	0.422	30.69	0.100	2.600
2022-143	9	M.B. RICCA			26	1.238	0.321	25.96	0.300	2.200
2022-143	24	Unicel DxH			15	0.593	0.118	19.91	0.200	0.900
2022-143	25	SYSMEX XN			24	0.904	0.127	14.09	0.500	1.300
2022-144	7	M.B.MANUAL			17	11.313	3.975	35.13	0	23.200
2022-144	9	M.B. RICCA			26	11.292	1.732	15.34	6.100	16.500
2022-144	24	Unicel DxH			15	7.500	0.602	8.03	5.600	9.400
2022-144	25	SYSMEX XN			24	4.592	0.947	20.63	1.700	7.400
2022-145	7	M.B.MANUAL			17	1.375	0.593	43.14	0	3.200
2022-145	9	M.B. RICCA			26	1.177	0.372	31.64	0.100	2.300
2022-145	24	Unicel DxH			15	0.587	0.109	18.53	0.300	0.900
2022-145	25	SYSMEX XN			24	0.833	0.114	13.71	0.500	1.200

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 138 SED. RATE (ESR)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
153	SED. RATE (ESR)	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 35 %	{GREATER}				
2022-151	4	SEDIPLAST		579	9.919	2.450	24.70	3.000	17.000	
2022-151	10	SEDI RATE		112	11.405	2.794	24.50	3.000	20.000	
2022-151	11	SEDIMAT-15		58	10.860	6.705	61.74	0	31.000	
2022-151	14	GLOBAL SC.		11	11.909	3.528	29.62	1.000	22.000	
2022-151	19	MINI CUBE		27	17.176	3.167	18.44	8.000	27.000	
2022-152	4	SEDIPLAST		579	53.382	8.985	16.83	26.000	80.000	
2022-152	10	SEDI RATE		112	52.055	9.691	18.62	23.000	81.000	
2022-152	11	SEDIMAT-15		58	126.551	27.041	21.37	45.000	208.000	
2022-152	14	GLOBAL SC.		11	59.909	9.922	16.56	30.000	90.000	
2022-152	19	MINI CUBE		27	66.235	14.111	21.30	24.000	109.000	
2022-153	4	SEDIPLAST		579	10.240	3.179	31.05	1.000	20.000	
2022-153	10	SEDI RATE		112	11.422	2.614	22.88	4.000	19.000	
2022-153	11	SEDIMAT-15		58	13.429	9.710	72.31	0	43.000	
2022-153	14	GLOBAL SC.		11	13.727	4.788	34.88	0	28.000	
2022-153	19	MINI CUBE		27	16.647	3.180	19.10	7.000	26.000	
2022-154	4	SEDIPLAST		579	10.211	2.810	27.52	2.000	19.000	
2022-154	10	SEDI RATE		112	11.560	3.152	27.27	2.000	21.000	
2022-154	11	SEDIMAT-15		58	12.245	7.971	65.09	0	36.000	
2022-154	14	GLOBAL SC.		11	13.727	3.305	24.08	4.000	24.000	
2022-154	19	MINI CUBE		27	17.118	3.496	20.42	7.000	28.000	
2022-155	4	SEDIPLAST		579	53.367	8.999	16.86	26.000	80.000	
2022-155	10	SEDI RATE		112	51.147	9.309	18.20	23.000	79.000	
2022-155	11	SEDIMAT-15		58	124.860	28.187	22.57	40.000	209.000	
2022-155	14	GLOBAL SC.		11	57.273	11.442	19.98	23.000	92.000	
2022-155	19	MINI CUBE		27	66.647	16.139	24.22	18.000	115.000	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH					
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}										
2022131X	1 SYSMEX CBC	1 NEUTROPHIL	20 SYSMEX XT-	14	62.764	4.021	6.41	47.100	78.500					
2022131X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	142	57.937	1.253	2.16	43.500	72.400					
2022131X	1 SYSMEX CBC	2 LYMPHOCYTE	20 SYSMEX XT-	14	20.293	4.016	19.79	15.200	25.400					
2022131X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	142	16.127	1.104	6.84	12.100	20.200					
2022131X	1 SYSMEX CBC	3 MONOCYTE	20 SYSMEX XT-	14	1.621	1.074	66.23	0	3.600					
2022131X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	142	1.447	0.313	21.61	0	3.400					
2022131X	1 SYSMEX CBC	4 EOSINOPHIL	20 SYSMEX XT-	14	14.564	0.888	6.10	10.900	18.200					
2022131X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	142	15.399	0.407	2.64	11.500	19.200					
2022131X	1 SYSMEX CBC	5 BASOPHIL	20 SYSMEX XT-	14	82.815	3.480	4.20	62.100	103.500					
2022131X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	142	9.096	0.839	9.22	6.800	11.400					
2022131X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	133	55.267	1.775	3.21	41.500	69.100					
2022131X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	27	55.148	2.036	3.69	41.400	68.900					
2022131X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	132	38.304	1.840	4.80	28.700	47.900					
2022131X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	27	34.774	2.191	6.30	26.100	43.500					
2022131X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	133	1.967	0.542	27.53	0.000	4.000					
2022131X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	27	2.296	0.368	16.01	0.300	4.300					
2022131X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	133	4.434	0.426	9.61	2.400	6.400					
2022131X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	27	4.659	0.476	10.21	2.700	6.700					
2022131X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	133	62.735	1.987	3.17	47.100	78.400					
2022131X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	27	3.135	0.073	2.33	1.100	5.100					
2022131X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	16	62.569	0.628	1.00	46.900	78.200					
2022131X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	16	23.200	0.518	2.23	17.400	29.000					
2022131X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	16	7.513	0.350	4.66	5.500	9.500					
2022131X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	16	3.644	0.631	17.33	1.600	5.600					
2022131X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	16	0.494	0.143	29.06	0	2.500					
2022131X	3 ADVIA 120	6 LUC	9 ADVIA-120	16	2.893	0.286	9.89	0.900	4.900					
2022131X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	123	77.523	0.771	0.99	58.100	96.900					
2022131X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	126	14.117	1.432	10.14	10.600	17.600					

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022131X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	124	4.187	0.505	12.07	2.200	6.200		
2022131X	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	124	3.545	0.220	6.19	1.500	5.500		
2022131X	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	122	0.532	0.247	46.39	0	2.500		
2022131X	5 BECTON D	1 NEUTROPHIL	29 B.C600,800	56	57.034	1.453	2.55	42.800	71.300		
2022131X	5 BECTON D	2 LYMPHOCYTE	29 B.C600,800	56	32.632	3.274	10.03	24.500	40.800		
2022131X	5 BECTON D	3 MONOCYTE	29 B.C600,800	56	5.813	1.933	33.25	3.800	7.800		
2022131X	5 BECTON D	4 EOSINOPHIL	29 B.C600,800	56	4.520	0.284	6.29	2.500	6.500		
2022131X	5 BECTON D	5 BASOPHIL	29 B.C600,800	56	0.000	0.000	0.00	0	2.000		
2022131X	6 MR Mindray	1 NEUTROPHIL	32 BC-5390	46	46.522	1.063	2.29	34.900	58.200		
2022131X	6 MR Mindray	2 LYMPHOCYTE	32 BC-5390	46	38.433	1.924	5.00	28.800	48.000		
2022131X	6 MR Mindray	3 MONOCYTE	32 BC-5390	46	7.282	1.214	16.67	5.300	9.300		
2022131X	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	45	7.789	1.132	14.53	5.800	9.800		
2022131X	6 MR Mindray	5 BASOPHIL	32 BC-5390	46	26.584	0.473	1.78	19.900	33.200		
2022131X	7 DXH	1 NEUTROPHIL	36 BC DXH 500	28	68.593	2.330	3.40	51.400	85.700		
2022131X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	28	25.881	1.873	7.24	19.400	32.400		
2022131X	7 DXH	3 MONOCYTE	36 BC DXH 500	28	0.337	0.363	107.78	0	2.300		
2022131X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	28	4.711	0.595	12.62	2.700	6.700		
2022131X	7 DXH	5 BASOPHIL	36 BC DXH 500	28	0.300	0.520	173.43	0	2.300		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2022132X	1 SYSMEX CBC	1 NEUTROPHIL	20 SYSMEX XT-	14	57.314	3.057	5.33	43.000	71.600		
2022132X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	142	55.496	1.811	3.26	41.600	69.400		
2022132X	1 SYSMEX CBC	2 LYMPHOCYTE	20 SYSMEX XT-	14	26.936	5.103	18.94	20.200	33.700		
2022132X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	142	19.872	1.505	7.57	14.900	24.800		
2022132X	1 SYSMEX CBC	3 MONOCYTE	20 SYSMEX XT-	14	2.307	0.386	16.74	0.300	4.300		
2022132X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	141	1.859	0.277	14.88	0	3.900		
2022132X	1 SYSMEX CBC	4 EOSINOPHIL	20 SYSMEX XT-	14	12.700	0.779	6.14	9.500	15.900		
2022132X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	142	13.967	0.752	5.39	10.500	17.500		
2022132X	1 SYSMEX CBC	5 BASOPHIL	20 SYSMEX XT-	14	83.562	1.140	1.36	62.700	104.500		
2022132X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	142	9.072	0.870	9.59	6.800	11.300		
2022132X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	133	71.715	1.384	1.93	53.800	89.600		
2022132X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	27	69.367	1.545	2.23	52.000	86.700		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022132X	2	ACT PENTRA	2 LYMPHOCYTE	15	COUL ACT 5	133	20.208	1.328	6.57	15.200	25.300
2022132X	2	ACT PENTRA	2 LYMPHOCYTE	24	ABX PENTRA	27	17.744	1.620	9.13	13.300	22.200
2022132X	2	ACT PENTRA	3 MONOCYTE	15	COUL ACT 5	133	2.360	0.551	23.35	0.400	4.400
2022132X	2	ACT PENTRA	3 MONOCYTE	24	ABX PENTRA	27	2.930	0.513	17.50	0.900	4.900
2022132X	2	ACT PENTRA	4 EOSINOPHIL	15	COUL ACT 5	133	5.633	0.387	6.87	3.600	7.600
2022132X	2	ACT PENTRA	4 EOSINOPHIL	24	ABX PENTRA	27	5.748	0.588	10.24	3.700	7.700
2022132X	2	ACT PENTRA	5 BASOPHIL	15	COUL ACT 5	133	83.245	1.740	2.09	62.400	104.100
2022132X	2	ACT PENTRA	5 BASOPHIL	24	ABX PENTRA	27	4.152	0.088	2.11	2.200	6.200
2022132X	3	ADVIA 120	1 NEUTROPHIL	9	ADVIA-120	16	75.181	0.963	1.28	56.400	94.000
2022132X	3	ADVIA 120	2 LYMPHOCYTE	9	ADVIA-120	16	11.319	0.378	3.34	8.500	14.100
2022132X	3	ADVIA 120	3 MONOCYTE	9	ADVIA-120	16	6.319	0.423	6.70	4.300	8.300
2022132X	3	ADVIA 120	4 EOSINOPHIL	9	ADVIA-120	16	5.519	0.842	15.26	3.500	7.500
2022132X	3	ADVIA 120	5 BASOPHIL	9	ADVIA-120	16	0.394	0.139	35.32	0	2.400
2022132X	3	ADVIA 120	6 LUC	9	ADVIA-120	16	1.560	0.196	12.56	0	3.600
2022132X	4	AB- CELL-D	1 NEUTROPHIL	8	CELL-DYN	124	68.032	0.769	1.13	51.000	85.000
2022132X	4	AB- CELL-D	2 LYMPHOCYTE	8	CELL-DYN	125	22.158	1.134	5.12	16.600	27.700
2022132X	4	AB- CELL-D	3 MONOCYTE	8	CELL-DYN	124	5.025	0.665	13.22	3.000	7.000
2022132X	4	AB- CELL-D	4 EOSINOPHIL	8	CELL-DYN	124	3.984	0.256	6.44	2.000	6.000
2022132X	4	AB- CELL-D	5 BASOPHIL	8	CELL-DYN	123	0.752	0.498	66.25	0	2.800
2022132X	5	BECTON D	1 NEUTROPHIL	29	B.C600,800	56	68.566	0.773	1.13	51.400	85.700
2022132X	5	BECTON D	2 LYMPHOCYTE	29	B.C600,800	56	21.645	0.813	3.75	16.200	27.100
2022132X	5	BECTON D	3 MONOCYTE	29	B.C600,800	56	6.209	0.444	7.16	4.200	8.200
2022132X	5	BECTON D	4 EOSINOPHIL	29	B.C600,800	56	3.511	0.294	8.39	1.500	5.500
2022132X	5	BECTON D	5 BASOPHIL	29	B.C600,800	56	0.029	0.045	156.12	0	2.000
2022132X	6	MR Mindray	1 NEUTROPHIL	32	BC-5390	45	61.839	1.147	1.86	46.400	77.300
2022132X	6	MR Mindray	2 LYMPHOCYTE	32	BC-5390	45	18.677	1.204	6.45	14.000	23.300
2022132X	6	MR Mindray	3 MONOCYTE	32	BC-5390	45	7.180	0.915	12.74	5.200	9.200
2022132X	6	MR Mindray	4 EOSINOPHIL	32	BC-5390	45	12.305	0.638	5.18	9.200	15.400
2022132X	6	MR Mindray	5 BASOPHIL	32	BC-5390	44	31.021	0.211	0.68	23.300	38.800
2022132X	7	DXH	1 NEUTROPHIL	36	BC DXH 500	28	82.526	1.387	1.68	61.900	103.200
2022132X	7	DXH	2 LYMPHOCYTE	36	BC DXH 500	28	8.054	0.985	12.23	6.000	10.100

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022132X	7 DXH	3 MONOCYTE	36 BC DXH 500	28	0.225	0.170	75.71	0	2.200		
2022132X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	28	8.881	0.620	6.98	6.700	11.100		
2022132X	7 DXH	5 BASOPHIL	36 BC DXH 500	28	0.011	0.031	288.68	0	2.000		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2022133X	1 SYSMEX CBC	1 NEUTROPHIL	20 SYSMEX XT-	14	53.257	2.429	4.56	39.900	66.600		
2022133X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	142	46.726	2.003	4.29	35.000	58.400		
2022133X	1 SYSMEX CBC	2 LYMPHOCYTE	20 SYSMEX XT-	14	29.050	2.793	9.61	21.800	36.300		
2022133X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	142	30.338	2.694	8.88	22.800	37.900		
2022133X	1 SYSMEX CBC	3 MONOCYTE	20 SYSMEX XT-	14	4.314	0.544	12.60	2.300	6.300		
2022133X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	142	2.844	0.453	15.92	0.800	4.800		
2022133X	1 SYSMEX CBC	4 EOSINOPHIL	20 SYSMEX XT-	14	12.843	0.481	3.74	9.600	16.100		
2022133X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	142	12.576	0.647	5.14	9.400	15.700		
2022133X	1 SYSMEX CBC	5 BASOPHIL	20 SYSMEX XT-	13	72.092	1.293	1.79	54.100	90.100		
2022133X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	142	7.455	0.708	9.49	5.500	9.500		
2022133X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	133	50.863	1.926	3.79	38.100	63.600		
2022133X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	27	51.307	2.731	5.32	38.500	64.100		
2022133X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	133	39.021	1.858	4.76	29.300	48.800		
2022133X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	27	34.889	2.824	8.10	26.200	43.600		
2022133X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	134	2.588	0.923	35.66	0.600	4.600		
2022133X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	27	3.437	0.872	25.38	1.400	5.400		
2022133X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	132	7.279	0.705	9.69	5.300	9.300		
2022133X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	27	7.441	0.819	11.01	5.400	9.400		
2022133X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	133	58.240	1.604	2.75	43.700	72.800		
2022133X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	27	2.974	0.064	2.16	1.000	5.000		
2022133X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	16	44.431	1.505	3.39	33.300	55.500		
2022133X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	16	34.681	1.610	4.64	26.000	43.400		
2022133X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	14.344	0.665	4.64	10.800	17.900		
2022133X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	16	1.988	0.428	21.56	0.000	4.000		
2022133X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	16	0.525	0.182	34.67	0	2.500		
2022133X	3 ADVIA 120	6 LUC	9 ADVIA-120	16	4.327	0.668	15.43	2.300	6.300		
2022133X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	124	77.539	0.799	1.03	58.200	96.900		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2022133X	4	AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	124	14.188	1.090	7.68	10.600	17.700
2022133X	4	AB- CELL-D	3	MONOCYTE	8	CELL-DYN	124	4.238	0.453	10.68	2.200	6.200
2022133X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	123	3.545	0.204	5.77	1.500	5.500
2022133X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	123	0.537	0.250	46.48	0	2.500
2022133X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	56	61.729	0.931	1.51	46.300	77.200
2022133X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	56	27.748	1.403	5.06	20.800	34.700
2022133X	5	BECTON D	3	MONOCYTE	29	B.C600,800	56	6.188	0.923	14.92	4.200	8.200
2022133X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	56	4.279	0.256	5.99	2.300	6.300
2022133X	5	BECTON D	5	BASOPHIL	29	B.C600,800	56	0.057	0.049	86.60	0	2.100
2022133X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	45	55.100	0.845	1.53	41.300	68.900
2022133X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	45	27.018	1.863	6.89	20.300	33.800
2022133X	6	MR Mindray	3	MONOCYTE	32	BC-5390	45	7.656	1.630	21.29	5.700	9.700
2022133X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	45	10.043	0.640	6.37	7.500	12.600
2022133X	6	MR Mindray	5	BASOPHIL	32	BC-5390	45	30.544	0.224	0.73	22.900	38.200
2022133X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	28	44.422	2.179	4.91	33.300	55.500
2022133X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	28	42.293	2.539	6.00	31.700	52.900
2022133X	7	DXH	3	MONOCYTE	36	BC DXH 500	28	0.333	0.448	134.41	0	2.300
2022133X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	28	12.457	1.243	9.98	9.300	15.600
2022133X	7	DXH	5	BASOPHIL	36	BC DXH 500	28	0.189	0.389	205.97	0	2.200
172 DIFF. WBC FOR 5 PAR.			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}						
2022134X	1	SYSMEX CBC	1	NEUTROPHIL	20	SYSMEX XT-	14	57.257	2.887	5.04	42.900	71.600
2022134X	1	SYSMEX CBC	1	NEUTROPHIL	25	XS SERIES	142	55.547	2.138	3.85	41.700	69.400
2022134X	1	SYSMEX CBC	2	LYMPHOCYTE	20	SYSMEX XT-	14	26.693	4.948	18.54	20.000	33.400
2022134X	1	SYSMEX CBC	2	LYMPHOCYTE	25	XS SERIES	142	19.634	1.755	8.94	14.700	24.500
2022134X	1	SYSMEX CBC	3	MONOCYTE	20	SYSMEX XT-	14	2.436	0.412	16.90	0.400	4.400
2022134X	1	SYSMEX CBC	3	MONOCYTE	25	XS SERIES	142	1.858	0.276	14.83	0	3.900
2022134X	1	SYSMEX CBC	4	EOSINOPHIL	20	SYSMEX XT-	14	12.864	0.927	7.21	9.600	16.100
2022134X	1	SYSMEX CBC	4	EOSINOPHIL	25	XS SERIES	142	14.065	0.820	5.83	10.500	17.600
2022134X	1	SYSMEX CBC	5	BASOPHIL	20	SYSMEX XT-	14	83.585	1.126	1.35	62.700	104.500
2022134X	1	SYSMEX CBC	5	BASOPHIL	25	XS SERIES	142	9.194	0.921	10.01	6.900	11.500
2022134X	2	ACT PENTRA	1	NEUTROPHIL	15	COUL ACT 5	133	50.825	2.268	4.46	38.100	63.500

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022134X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	27	50.741	2.508	4.94	38.100	63.400		
2022134X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	133	39.047	2.101	5.38	29.300	48.800		
2022134X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	27	34.974	2.799	8.00	26.200	43.700		
2022134X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	132	2.621	0.907	34.59	0.600	4.600		
2022134X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	27	3.737	0.816	21.83	1.700	5.700		
2022134X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	134	7.447	0.786	10.55	5.400	9.400		
2022134X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	27	7.567	0.796	10.52	5.600	9.600		
2022134X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	133	58.393	1.498	2.57	43.800	73.000		
2022134X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	27	2.952	0.057	1.93	1.000	5.000		
2022134X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	16	43.831	1.341	3.06	32.900	54.800		
2022134X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	16	35.263	1.314	3.73	26.400	44.100		
2022134X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	17	14.225	0.900	6.32	10.700	17.800		
2022134X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	16	1.900	0.530	27.91	0	3.900		
2022134X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	15	0.607	0.198	32.67	0	2.600		
2022134X	3 ADVIA 120	6 LUC	9 ADVIA-120	16	4.600	0.506	11.00	2.600	6.600		
2022134X	4 AB- CELL-D	1 NEUTROPHIL	8 CELL-DYN	124	53.024	1.744	3.29	39.800	66.300		
2022134X	4 AB- CELL-D	2 LYMPHOCYTE	8 CELL-DYN	124	35.397	2.335	6.60	26.500	44.200		
2022134X	4 AB- CELL-D	3 MONOCYTE	8 CELL-DYN	123	6.629	1.139	17.19	4.600	8.600		
2022134X	4 AB- CELL-D	4 EOSINOPHIL	8 CELL-DYN	124	3.836	0.415	10.81	1.800	5.800		
2022134X	4 AB- CELL-D	5 BASOPHIL	8 CELL-DYN	124	0.935	0.654	69.93	0	2.900		
2022134X	5 BECTON D	1 NEUTROPHIL	29 B.C600,800	56	68.629	0.830	1.21	51.500	85.800		
2022134X	5 BECTON D	2 LYMPHOCYTE	29 B.C600,800	56	21.496	0.782	3.64	16.100	26.900		
2022134X	5 BECTON D	3 MONOCYTE	29 B.C600,800	56	6.315	0.566	8.96	4.300	8.300		
2022134X	5 BECTON D	4 EOSINOPHIL	29 B.C600,800	56	3.446	0.188	5.45	1.400	5.400		
2022134X	5 BECTON D	5 BASOPHIL	29 B.C600,800	56	0.045	0.050	111.36	0	2.000		
2022134X	6 MR Mindray	1 NEUTROPHIL	32 BC-5390	45	61.823	1.145	1.85	46.400	77.300		
2022134X	6 MR Mindray	2 LYMPHOCYTE	32 BC-5390	45	18.720	0.983	5.25	14.000	23.400		
2022134X	6 MR Mindray	3 MONOCYTE	32 BC-5390	45	7.189	0.884	12.29	5.200	9.200		
2022134X	6 MR Mindray	4 EOSINOPHIL	32 BC-5390	45	12.268	0.734	5.98	9.200	15.300		
2022134X	6 MR Mindray	5 BASOPHIL	32 BC-5390	45	31.007	0.197	0.64	23.300	38.800		
2022134X	7 DXH	1 NEUTROPHIL	36 BC DXH 500	28	44.530	2.786	6.26	33.400	55.700		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022134X	7 DXH	2 LYMPHOCYTE	36 BC DXH 500	28	42.611	3.260	7.65	32.000	53.300		
2022134X	7 DXH	3 MONOCYTE	36 BC DXH 500	28	0.200	0.125	62.36	0	2.200		
2022134X	7 DXH	4 EOSINOPHIL	36 BC DXH 500	28	12.389	1.309	10.56	9.300	15.500		
2022134X	7 DXH	5 BASOPHIL	36 BC DXH 500	28	0.059	0.056	94.79	0	2.100		
172 DIFF. WBC FOR 5 PAR.		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2022135X	1 SYSMEX CBC	1 NEUTROPHIL	20 SYSMEX XT-	14	53.457	2.650	4.96	40.100	66.800		
2022135X	1 SYSMEX CBC	1 NEUTROPHIL	25 XS SERIES	141	46.595	2.034	4.37	34.900	58.200		
2022135X	1 SYSMEX CBC	2 LYMPHOCYTE	20 SYSMEX XT-	14	28.943	2.635	9.10	21.700	36.200		
2022135X	1 SYSMEX CBC	2 LYMPHOCYTE	25 XS SERIES	142	30.385	2.660	8.75	22.800	38.000		
2022135X	1 SYSMEX CBC	3 MONOCYTE	20 SYSMEX XT-	14	4.200	0.846	20.14	2.200	6.200		
2022135X	1 SYSMEX CBC	3 MONOCYTE	25 XS SERIES	142	2.885	0.463	16.06	0.900	4.900		
2022135X	1 SYSMEX CBC	4 EOSINOPHIL	20 SYSMEX XT-	14	12.757	0.417	3.27	9.600	15.900		
2022135X	1 SYSMEX CBC	4 EOSINOPHIL	25 XS SERIES	143	12.571	0.750	5.96	9.400	15.700		
2022135X	1 SYSMEX CBC	5 BASOPHIL	20 SYSMEX XT-	14	71.646	1.584	2.21	53.700	89.600		
2022135X	1 SYSMEX CBC	5 BASOPHIL	25 XS SERIES	142	7.416	1.284	17.31	5.400	9.400		
2022135X	2 ACT PENTRA	1 NEUTROPHIL	15 COUL ACT 5	133	71.775	1.324	1.84	53.800	89.700		
2022135X	2 ACT PENTRA	1 NEUTROPHIL	24 ABX PENTRA	27	69.385	1.409	2.03	52.000	86.700		
2022135X	2 ACT PENTRA	2 LYMPHOCYTE	15 COUL ACT 5	134	20.035	1.420	7.09	15.000	25.000		
2022135X	2 ACT PENTRA	2 LYMPHOCYTE	24 ABX PENTRA	27	17.526	1.370	7.82	13.100	21.900		
2022135X	2 ACT PENTRA	3 MONOCYTE	15 COUL ACT 5	131	2.352	0.615	26.14	0.400	4.400		
2022135X	2 ACT PENTRA	3 MONOCYTE	24 ABX PENTRA	27	2.948	0.545	18.47	0.900	4.900		
2022135X	2 ACT PENTRA	4 EOSINOPHIL	15 COUL ACT 5	132	5.669	0.473	8.34	3.700	7.700		
2022135X	2 ACT PENTRA	4 EOSINOPHIL	24 ABX PENTRA	27	5.889	0.632	10.73	3.900	7.900		
2022135X	2 ACT PENTRA	5 BASOPHIL	15 COUL ACT 5	134	82.899	1.926	2.32	62.200	103.600		
2022135X	2 ACT PENTRA	5 BASOPHIL	24 ABX PENTRA	27	4.152	0.096	2.31	2.200	6.200		
2022135X	3 ADVIA 120	1 NEUTROPHIL	9 ADVIA-120	16	75.213	0.903	1.20	56.400	94.000		
2022135X	3 ADVIA 120	2 LYMPHOCYTE	9 ADVIA-120	16	11.281	0.286	2.53	8.500	14.100		
2022135X	3 ADVIA 120	3 MONOCYTE	9 ADVIA-120	16	6.375	0.327	5.13	4.400	8.400		
2022135X	3 ADVIA 120	4 EOSINOPHIL	9 ADVIA-120	16	5.450	0.816	14.98	3.500	7.500		
2022135X	3 ADVIA 120	5 BASOPHIL	9 ADVIA-120	16	0.431	0.104	24.21	0	2.400		
2022135X	3 ADVIA 120	6 LUC	9 ADVIA-120	16	1.560	0.185	11.89	0	3.600		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 125 DIFF. FOR 5 PAR NEW

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022135X	4	AB- CELL-D	1	NEUTROPHIL	8	CELL-DYN	124	68.022	0.930	1.37	51.000	85.000
2022135X	4	AB- CELL-D	2	LYMPHOCYTE	8	CELL-DYN	124	22.177	1.126	5.08	16.600	27.700
2022135X	4	AB- CELL-D	3	MONOCYTE	8	CELL-DYN	124	5.075	0.604	11.91	3.100	7.100
2022135X	4	AB- CELL-D	4	EOSINOPHIL	8	CELL-DYN	124	3.930	0.340	8.65	1.900	5.900
2022135X	4	AB- CELL-D	5	BASOPHIL	8	CELL-DYN	124	0.738	0.481	65.16	0	2.700
2022135X	5	BECTON D	1	NEUTROPHIL	29	B.C600,800	56	62.148	0.960	1.54	46.600	77.700
2022135X	5	BECTON D	2	LYMPHOCYTE	29	B.C600,800	56	27.330	1.503	5.50	20.500	34.200
2022135X	5	BECTON D	3	MONOCYTE	29	B.C600,800	56	6.245	0.799	12.80	4.200	8.200
2022135X	5	BECTON D	4	EOSINOPHIL	29	B.C600,800	56	4.232	0.254	6.01	2.200	6.200
2022135X	5	BECTON D	5	BASOPHIL	29	B.C600,800	56	0.045	0.050	111.36	0	2.000
2022135X	6	MR Mindray	1	NEUTROPHIL	32	BC-5390	45	55.070	0.934	1.70	41.300	68.800
2022135X	6	MR Mindray	2	LYMPHOCYTE	32	BC-5390	45	26.818	1.835	6.84	20.100	33.500
2022135X	6	MR Mindray	3	MONOCYTE	32	BC-5390	45	7.951	1.767	22.22	6.000	10.000
2022135X	6	MR Mindray	4	EOSINOPHIL	32	BC-5390	45	9.989	0.521	5.22	7.500	12.500
2022135X	6	MR Mindray	5	BASOPHIL	32	BC-5390	45	30.568	0.280	0.92	22.900	38.200
2022135X	7	DXH	1	NEUTROPHIL	36	BC DXH 500	28	82.007	1.216	1.48	61.500	102.500
2022135X	7	DXH	2	LYMPHOCYTE	36	BC DXH 500	28	8.604	1.238	14.39	6.500	10.800
2022135X	7	DXH	3	MONOCYTE	36	BC DXH 500	28	0.268	0.175	65.47	0	2.300
2022135X	7	DXH	4	EOSINOPHIL	36	BC DXH 500	28	8.961	0.787	8.78	6.700	11.200
2022135X	7	DXH	5	BASOPHIL	36	BC DXH 500	28	0.033	0.082	244.95	0	2.000

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
185 Diff 6 Parameter Ins			CLIA TEST ID #: 765			EVALUATION CRITERIA: TARGET VALUE			25 % OR 2.00 {GREATER}			
2022131Y	1	6 PAR REG	1	NEUTROPHIL	31	SYSMEX XN	37	60.154	1.111	1.85	45.100	75.200
2022131Y	1	6 PAR REG	1	NEUTROPHIL	35	SYS XNL SR	76	56.655	1.335	2.36	42.500	70.800
2022131Y	1	6 PAR REG	2	LYMPHOCYTE	31	SYSMEX XN	37	16.739	0.976	5.83	12.600	20.900

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022131Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	76	17.959	1.387	7.72	13.500	22.400		
2022131Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	37	2.539	0.475	18.71	0.500	4.500		
2022131Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	76	1.448	0.342	23.62	0	3.400		
2022131Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	37	15.383	0.706	4.59	11.500	19.200		
2022131Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	76	15.212	0.681	4.47	11.400	19.000		
2022131Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	37	5.100	1.359	26.64	3.100	7.100		
2022131Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	76	8.753	0.805	9.20	6.600	10.900		
2022131Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	37	14.439	0.562	3.89	10.800	18.000		
2022131Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	76	15.163	0.750	4.95	11.400	19.000		
2022131Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	18	0.000	0.000	0.00	0	2.000		
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}							
2022132Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	37	57.908	1.576	2.72	43.400	72.400		
2022132Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	76	54.988	2.440	4.44	41.200	68.700		
2022132Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	37	19.772	1.007	5.09	14.800	24.700		
2022132Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	76	20.918	1.930	9.23	15.700	26.100		
2022132Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	37	2.894	0.647	22.36	0.900	4.900		
2022132Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	76	1.474	0.332	22.52	0	3.500		
2022132Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	38	14.128	1.119	7.92	10.600	17.700		
2022132Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	76	14.395	1.121	7.79	10.800	18.000		
2022132Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	36	5.047	1.752	34.71	3.000	7.000		
2022132Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	76	8.448	0.742	8.78	6.300	10.600		
2022132Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	37	14.900	0.803	5.39	11.200	18.600		
2022132Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	76	15.208	1.027	6.75	11.400	19.000		
2022132Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	18	0.100	0.108	108.47	0	2.100		
2022133Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	37	48.240	1.005	2.08	36.200	60.300		
2022133Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	76	46.224	1.926	4.17	34.700	57.800		
2022133Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	37	29.308	1.675	5.72	22.000	36.600		
2022133Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	76	31.396	2.207	7.03	23.500	39.200		
2022133Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	37	4.874	0.624	12.79	2.900	6.900		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 127 DIFF 6 PARAM INSTRUM

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2022133Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	76	3.012	0.565	18.77	1.000	5.000			
2022133Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	37	12.369	0.448	3.62	9.300	15.500			
2022133Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	76	12.441	0.839	6.74	9.300	15.600			
2022133Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	37	5.060	0.713	14.10	3.100	7.100			
2022133Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	76	7.175	0.646	9.00	5.200	9.200			
2022133Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	37	11.644	0.355	3.05	8.700	14.600			
2022133Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	76	12.466	0.749	6.01	9.300	15.600			
2022133Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	18	0.000	0.000	0.00	0	2.000			
185 Diff 6 Parameter Ins		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}								
2022134Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	37	57.783	1.449	2.51	43.300	72.200			
2022134Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	76	54.958	2.272	4.13	41.200	68.700			
2022134Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	37	19.775	1.086	5.49	14.800	24.700			
2022134Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	76	21.070	1.663	7.89	15.800	26.300			
2022134Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	37	2.922	0.820	28.05	0.900	4.900			
2022134Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	76	1.474	0.352	23.90	0	3.500			
2022134Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	37	14.283	1.212	8.49	10.700	17.900			
2022134Y	1 6 PAR REG	4 EOSINOPHIL	35 SYS XNL SR	76	14.414	1.122	7.78	10.800	18.000			
2022134Y	1 6 PAR REG	5 BASOPHIL	31 SYSMEX XN	37	4.965	1.628	32.79	3.000	7.000			
2022134Y	1 6 PAR REG	5 BASOPHIL	35 SYS XNL SR	77	8.470	0.787	9.29	6.400	10.600			
2022134Y	1 6 PAR REG	6 IMMATURE G	31 SYSMEX XN	37	15.014	0.754	5.02	11.300	18.800			
2022134Y	1 6 PAR REG	6 IMMATURE G	35 SYS XNL SR	75	15.165	0.992	6.54	11.400	19.000			
2022134Y	1 6 PAR REG	7 NRBC	31 SYSMEX XN	18	0.053	0.078	146.57	0	2.100			
2022135Y	1 6 PAR REG	1 NEUTROPHIL	31 SYSMEX XN	37	48.189	1.017	2.11	36.100	60.200			
2022135Y	1 6 PAR REG	1 NEUTROPHIL	35 SYS XNL SR	76	46.357	2.158	4.65	34.800	57.900			
2022135Y	1 6 PAR REG	2 LYMPHOCYTE	31 SYSMEX XN	37	29.486	1.537	5.21	22.100	36.900			
2022135Y	1 6 PAR REG	2 LYMPHOCYTE	35 SYS XNL SR	76	31.363	2.054	6.55	23.500	39.200			
2022135Y	1 6 PAR REG	3 MONOCYTE	31 SYSMEX XN	37	4.711	0.727	15.44	2.700	6.700			
2022135Y	1 6 PAR REG	3 MONOCYTE	35 SYS XNL SR	76	3.048	0.454	14.90	1.000	5.000			
2022135Y	1 6 PAR REG	4 EOSINOPHIL	31 SYSMEX XN	37	12.519	0.474	3.79	9.400	15.600			

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 127 DIFF 6 PARAM INSTRUM									
ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2022135Y	1 6 PAR REG	4	EOSINOPHIL	35	SYS XNL SR	75	12.436	0.776	6.24	9.300	15.500		
2022135Y	1 6 PAR REG	5	BASOPHIL	31	SYSMEX XN	36	5.047	0.578	11.46	3.000	7.000		
2022135Y	1 6 PAR REG	5	BASOPHIL	35	SYS XNL SR	77	7.162	0.817	11.40	5.200	9.200		
2022135Y	1 6 PAR REG	6	IMMATURE G	31	SYSMEX XN	37	11.667	0.420	3.60	8.800	14.600		
2022135Y	1 6 PAR REG	6	IMMATURE G	35	SYS XNL SR	76	12.471	0.631	5.06	9.400	15.600		
2022135Y	1 6 PAR REG	7	NRBC	31	SYSMEX XN	18	0.000	0.000	0.00	0	2.000		

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 128 DIFF 3 PARAMETER INS										
ANALYTE														
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH					
186 DIFF 3 PARAMETER INS		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}										
2022131Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	26	30.786	0.866	2.81	23.100	38.500			
2022131Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	40	31.074	1.312	4.22	23.300	38.800			
2022131Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	25	17.070	0.856	5.01	12.800	21.300			
2022131Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	40	12.972	1.266	9.76	9.700	16.200			
2022131Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	25	52.100	0.907	1.74	39.100	65.100			
2022131Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	40	55.923	2.062	3.69	41.900	69.900			
2022131Z	9 3D	1	Lymphocyte	2	AcT Diff 2	12	31.343	1.113	3.55	23.500	39.200			
2022131Z	9 3D	1	Lymphocyte	4	JT - Coult	12	30.533	1.410	4.62	22.900	38.200			
2022131Z	9 3D	1	Lymphocyte	6	Emerald Gr	11	29.336	0.568	1.94	22.000	36.700			
2022131Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	12	7.700	0.316	4.11	5.700	9.700			
2022131Z	9 3D	2	Mix M/E/Ba	4	JT - Coult	11	6.036	0.936	15.51	4.000	8.000			
2022131Z	9 3D	2	Mix M/E/Ba	6	Emerald Gr	11	5.245	0.370	7.06	3.200	7.200			
2022131Z	9 3D	3	Neutrophil	2	AcT Diff 2	12	60.943	1.225	2.01	45.700	76.200			
2022131Z	9 3D	3	Neutrophil	4	JT - Coult	11	63.091	1.618	2.57	47.300	78.900			
2022131Z	9 3D	3	Neutrophil	6	Emerald Gr	11	65.418	0.803	1.23	49.100	81.800			
2022132Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	25	62.284	0.450	0.72	46.700	77.900			
2022132Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	40	60.949	1.526	2.50	45.700	76.200			

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE													
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH				
2022132Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	25	14.110	0.793	5.62	10.600	17.600		
2022132Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	39	11.247	1.073	9.54	8.400	14.100		
2022132Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	25	23.715	0.910	3.84	17.800	29.600		
2022132Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	39	27.784	1.392	5.01	20.800	34.700		
2022132Z	9 3D	1	Lymphocyte	2	AcT Diff 2	13	13.875	0.776	5.59	10.400	17.300		
2022132Z	9 3D	1	Lymphocyte	4	JT - Coult	12	13.342	0.914	6.85	10.000	16.700		
2022132Z	9 3D	1	Lymphocyte	6	Emerald Gr	11	13.955	1.010	7.24	10.500	17.400		
2022132Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	12	5.614	0.473	8.43	3.600	7.600		
2022132Z	9 3D	2	Mix M/E/Ba	4	JT - Coult	11	4.864	0.676	13.90	2.900	6.900		
2022132Z	9 3D	2	Mix M/E/Ba	6	Emerald Gr	11	2.373	0.242	10.18	0.400	4.400		
2022132Z	9 3D	3	Neutrophil	2	AcT Diff 2	12	80.700	0.910	1.13	60.500	100.900		
2022132Z	9 3D	3	Neutrophil	4	JT - Coult	11	81.664	0.936	1.15	61.200	102.100		
2022132Z	9 3D	3	Neutrophil	6	Emerald Gr	11	83.673	1.212	1.45	62.800	104.600		
186 DIFF 3 PARAMETER INS		CLIA TEST ID #: 765		EVALUATION CRITERIA: TARGET VALUE 25 % OR 2.00 {GREATER}									
2022133Z	8 3ST	1	Lymphocyte	1	KX 21 - Sy	25	12.845	1.051	8.18	9.600	16.100		
2022133Z	8 3ST	1	Lymphocyte	3	ABBOTT C-D	40	16.521	2.028	12.28	12.400	20.700		
2022133Z	8 3ST	2	Mix M/E/Ba	1	KX 21 - Sy	25	17.790	1.429	8.03	13.300	22.200		
2022133Z	8 3ST	2	Mix M/E/Ba	3	ABBOTT C-D	41	12.465	2.322	18.63	9.300	15.600		
2022133Z	8 3ST	3	Neutrophil	1	KX 21 - Sy	25	69.595	1.051	1.51	52.200	87.000		
2022133Z	8 3ST	3	Neutrophil	3	ABBOTT C-D	39	70.655	2.380	3.37	53.000	88.300		
2022133Z	9 3D	1	Lymphocyte	2	AcT Diff 2	12	56.443	1.184	2.10	42.300	70.600		
2022133Z	9 3D	1	Lymphocyte	4	JT - Coult	12	58.942	2.101	3.56	44.200	73.700		
2022133Z	9 3D	1	Lymphocyte	6	Emerald Gr	11	52.555	2.181	4.15	39.400	65.700		
2022133Z	9 3D	2	Mix M/E/Ba	2	AcT Diff 2	12	10.886	1.607	14.76	8.200	13.600		
2022133Z	9 3D	2	Mix M/E/Ba	4	JT - Coult	11	8.764	1.644	18.76	6.600	11.000		
2022133Z	9 3D	2	Mix M/E/Ba	6	Emerald Gr	11	9.509	0.911	9.58	7.100	11.900		
2022133Z	9 3D	3	Neutrophil	2	AcT Diff 2	12	32.814	1.992	6.07	24.600	41.000		
2022133Z	9 3D	3	Neutrophil	4	JT - Coult	11	31.982	1.502	4.70	24.000	40.000		
2022133Z	9 3D	3	Neutrophil	6	Emerald Gr	11	37.936	2.133	5.62	28.500	47.400		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 128 DIFF 3 PARAMETER INS

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
186	DIFF 3 PARAMETER INS	CLIA TEST ID #: 765	EVALUATION CRITERIA: TARGET VALUE	25	% OR 2.00	{GREATER}							
2022134Z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	25	12.485	1.223	9.79	9.400	15.600				
2022134Z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	40	14.682	1.766	12.03	11.000	18.400				
2022134Z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	25	17.755	0.918	5.17	13.300	22.200				
2022134Z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	40	12.962	1.383	10.67	9.700	16.200				
2022134Z	8 3ST	3 Neutrophil	1 KX 21 - Sy	25	69.760	0.961	1.38	52.300	87.200				
2022134Z	8 3ST	3 Neutrophil	3 ABBOTT C-D	40	72.336	2.485	3.44	54.300	90.400				
2022134Z	9 3D	1 Lymphocyte	2 AcT Diff 2	12	58.100	1.676	2.88	43.600	72.600				
2022134Z	9 3D	1 Lymphocyte	4 JT - Coult	12	59.225	3.182	5.37	44.400	74.000				
2022134Z	9 3D	1 Lymphocyte	6 Emerald Gr	11	53.282	1.362	2.56	40.000	66.600				
2022134Z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	12	10.486	1.567	14.94	7.900	13.100				
2022134Z	9 3D	2 Mix M/E/Ba	4 JT - Coult	11	8.709	1.610	18.49	6.500	10.900				
2022134Z	9 3D	2 Mix M/E/Ba	6 Emerald Gr	11	9.600	0.821	8.56	7.200	12.000				
2022134Z	9 3D	3 Neutrophil	2 AcT Diff 2	12	31.414	2.065	6.57	23.600	39.300				
2022134Z	9 3D	3 Neutrophil	4 JT - Coult	11	31.282	1.831	5.85	23.500	39.100				
2022134Z	9 3D	3 Neutrophil	6 Emerald Gr	11	37.118	1.231	3.32	27.800	46.400				
2022135Z	8 3ST	1 Lymphocyte	1 KX 21 - Sy	25	62.130	0.908	1.46	46.600	77.700				
2022135Z	8 3ST	1 Lymphocyte	3 ABBOTT C-D	40	61.026	1.602	2.63	45.800	76.300				
2022135Z	8 3ST	2 Mix M/E/Ba	1 KX 21 - Sy	25	13.845	0.679	4.91	10.400	17.300				
2022135Z	8 3ST	2 Mix M/E/Ba	3 ABBOTT C-D	39	11.229	1.059	9.43	8.400	14.000				
2022135Z	8 3ST	3 Neutrophil	1 KX 21 - Sy	24	24.095	0.721	2.99	18.100	30.100				
2022135Z	8 3ST	3 Neutrophil	3 ABBOTT C-D	40	27.772	1.571	5.66	20.800	34.700				
2022135Z	9 3D	1 Lymphocyte	2 AcT Diff 2	12	13.543	0.403	2.98	10.200	16.900				
2022135Z	9 3D	1 Lymphocyte	4 JT - Coult	12	13.850	1.020	7.37	10.400	17.300				
2022135Z	9 3D	1 Lymphocyte	6 Emerald Gr	11	14.000	0.994	7.10	10.500	17.500				
2022135Z	9 3D	2 Mix M/E/Ba	2 AcT Diff 2	12	5.814	0.745	12.82	3.800	7.800				
2022135Z	9 3D	2 Mix M/E/Ba	4 JT - Coult	11	4.564	0.647	14.18	2.600	6.600				
2022135Z	9 3D	2 Mix M/E/Ba	6 Emerald Gr	11	2.300	0.209	9.08	0.300	4.300				
2022135Z	9 3D	3 Neutrophil	2 AcT Diff 2	11	80.967	0.776	0.96	60.700	101.200				

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 128 DIFF 3 PARAMETER INS									
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022135Z	9 3D	3	Neutrophil	4	JT - Coult	11	81.409	0.962	1.18	61.100	101.800		
2022135Z	9 3D	3	Neutrophil	6	Emerald Gr	11	83.700	1.129	1.35	62.800	104.600		
SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW									
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775		EVALUATION CRITERIA: TARGET VALUE 6 %									
2022-131	1 Sysmex CBC	127	SYSMEX XT	13	2.388	0.032	1.35	2.240	2.530				
2022-131	1 Sysmex CBC	132	SYSMEX XS	146	2.310	0.027	1.18	2.170	2.450				
2022-131	1 Sysmex CBC	141	SYSMEX XN	46	2.286	0.027	1.17	2.150	2.420				
2022-131	1 Sysmex CBC	152	Sysmex XN	71	2.278	0.028	1.21	2.140	2.420				
2022-131	2 ACT PENTRA	125	COULTER AC	131	4.632	0.068	1.47	4.350	4.910				
2022-131	2 ACT PENTRA	130	ABX PENTRA	27	4.613	0.062	1.34	4.340	4.890				
2022-131	3 ADVIA 120	116	ADVIA-120	16	4.518	0.118	2.61	4.250	4.790				
2022-131	4 AB-CELL DY	115	ABBOTT C-D	121	5.175	0.164	3.17	4.860	5.490				
2022-131	5 BECTON D	137	B.C DXH	55	2.489	0.036	1.46	2.340	2.640				
2022-131	6 MR Mindray	145	BC-5390	45	2.255	0.036	1.61	2.120	2.390				
2022-131	7 DXH500 Ser	149	BC DXH 500	28	4.715	0.069	1.46	4.430	5.000				
2022-131	8 3 ST	84	ABBOTT C-D	37	4.313	0.091	2.11	4.050	4.570				
2022-131	8 3 ST	98	SYSMEX K-	11	4.220	0.040	0.95	3.970	4.470				
2022-131	8 3 ST	138	SY KX-21N	19	4.243	0.047	1.11	3.990	4.500				
2022-131	9 3 D	33	COULTER JT	12	4.686	0.065	1.39	4.400	4.970				
2022-131	9 3 D	120	COULTER	20	4.635	0.131	2.82	4.360	4.910				
2022-132	1 Sysmex CBC	127	SYSMEX XT	13	5.734	0.112	1.95	5.390	6.080				
2022-132	1 Sysmex CBC	132	SYSMEX XS	146	5.696	0.062	1.09	5.350	6.040				
2022-132	1 Sysmex CBC	141	SYSMEX XN	46	5.733	0.081	1.41	5.390	6.080				
2022-132	1 Sysmex CBC	152	Sysmex XN	71	5.749	0.068	1.19	5.400	6.090				
2022-132	2 ACT PENTRA	125	COULTER AC	131	5.150	0.072	1.41	4.840	5.460				

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-132	2	ACT PENTRA	130 ABX PENTRA	27	5.134	0.068	1.33	4.830	5.440
2022-132	3	ADVIA 120	116 ADVIA-120	16	5.202	0.103	1.98	4.890	5.510
2022-132	4	AB-CELL DY	115 ABBOTT C-D	121	4.433	0.151	3.40	4.170	4.700
2022-132	5	BECTON D	137 B.C DXH	55	5.357	0.080	1.50	5.040	5.680
2022-132	6	MR Mindray	145 BC-5390	45	5.225	0.085	1.63	4.910	5.540
2022-132	7	DXH500 Ser	149 BC DXH 500	28	5.250	0.059	1.13	4.940	5.570
2022-132	8	3 ST	84 ABBOTT C-D	37	5.575	0.084	1.50	5.240	5.910
2022-132	8	3 ST	98 SYSMEX K-	11	5.513	0.058	1.06	5.180	5.840
2022-132	8	3 ST	138 SY KX-21N	19	5.525	0.045	0.81	5.190	5.860
2022-132	9	3 D	33 COULTER JT	12	5.726	0.068	1.18	5.380	6.070
2022-132	9	3 D	120 COULTER	20	5.696	0.127	2.23	5.350	6.040
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %						
2022-133	1	Sysmex CBC	127 SYSMEX XT	13	4.837	0.063	1.30	4.550	5.130
2022-133	1	Sysmex CBC	132 SYSMEX XS	146	4.764	0.056	1.17	4.480	5.050
2022-133	1	Sysmex CBC	141 SYSMEX XN	46	4.783	0.051	1.07	4.500	5.070
2022-133	1	Sysmex CBC	152 Sysmex XN	71	4.770	0.047	0.99	4.480	5.060
2022-133	2	ACT PENTRA	125 COULTER AC	131	2.308	0.058	2.50	2.170	2.450
2022-133	2	ACT PENTRA	130 ABX PENTRA	27	2.315	0.047	2.03	2.180	2.450
2022-133	3	ADVIA 120	116 ADVIA-120	16	2.236	0.033	1.49	2.100	2.370
2022-133	4	AB-CELL DY	115 ABBOTT C-D	121	5.167	0.187	3.61	4.860	5.480
2022-133	5	BECTON D	137 B.C DXH	55	4.109	0.063	1.53	3.860	4.360
2022-133	6	MR Mindray	145 BC-5390	45	4.477	0.074	1.65	4.210	4.750
2022-133	7	DXH500 Ser	149 BC DXH 500	28	2.361	0.047	1.99	2.220	2.500
2022-133	8	3 ST	84 ABBOTT C-D	37	2.360	0.062	2.62	2.220	2.500
2022-133	8	3 ST	98 SYSMEX K-	11	2.307	0.045	1.94	2.170	2.450
2022-133	8	3 ST	138 SY KX-21N	19	2.318	0.023	1.01	2.180	2.460
2022-133	9	3 D	33 COULTER JT	12	2.291	0.039	1.70	2.150	2.430
2022-133	9	3 D	120 COULTER	20	2.320	0.058	2.49	2.180	2.460
2022-134	1	Sysmex CBC	127 SYSMEX XT	13	5.735	0.105	1.83	5.390	6.080

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-134	1	Sysmex CBC	132 SYSMEX XS	146	5.699	0.068	1.20	5.360	6.040		
2022-134	1	Sysmex CBC	141 SYSMEX XN	46	5.741	0.074	1.29	5.400	6.090		
2022-134	1	Sysmex CBC	152 Sysmex XN	71	5.749	0.060	1.05	5.400	6.090		
2022-134	2	ACT PENTRA	125 COULTER AC	131	2.306	0.050	2.18	2.170	2.440		
2022-134	2	ACT PENTRA	130 ABX PENTRA	27	2.312	0.049	2.11	2.170	2.450		
2022-134	3	ADVIA 120	116 ADVIA-120	16	2.231	0.045	2.01	2.100	2.360		
2022-134	4	AB-CELL DY	115 ABBOTT C-D	121	2.011	0.055	2.73	1.890	2.130		
2022-134	5	BECTON D	137 B.C DXH	55	5.371	0.065	1.20	5.050	5.690		
2022-134	6	MR Mindray	145 BC-5390	45	5.226	0.092	1.75	4.910	5.540		
2022-134	7	DXH500 Ser	149 BC DXH 500	28	2.364	0.040	1.71	2.220	2.510		
2022-134	8	3 ST	84 ABBOTT C-D	37	2.345	0.068	2.91	2.200	2.490		
2022-134	8	3 ST	98 SYSMEX K-	11	2.325	0.025	1.08	2.190	2.460		
2022-134	8	3 ST	138 SY KX-21N	19	2.328	0.025	1.06	2.190	2.470		
2022-134	9	3 D	33 COULTER JT	12	2.287	0.046	2.03	2.150	2.420		
2022-134	9	3 D	120 COULTER	20	2.315	0.064	2.77	2.180	2.450		
549	RED CELL COUNT (RBC)	CLIA TEST ID #: 775	EVALUATION CRITERIA: TARGET VALUE 6 %								
2022-135	1	Sysmex CBC	127 SYSMEX XT	13	4.856	0.072	1.48	4.560	5.150		
2022-135	1	Sysmex CBC	132 SYSMEX XS	146	4.762	0.051	1.07	4.480	5.050		
2022-135	1	Sysmex CBC	141 SYSMEX XN	46	4.786	0.056	1.17	4.500	5.070		
2022-135	1	Sysmex CBC	152 Sysmex XN	71	4.768	0.054	1.12	4.480	5.050		
2022-135	2	ACT PENTRA	125 COULTER AC	131	5.137	0.069	1.33	4.830	5.450		
2022-135	2	ACT PENTRA	130 ABX PENTRA	27	5.132	0.069	1.34	4.820	5.440		
2022-135	3	ADVIA 120	116 ADVIA-120	16	5.202	0.137	2.64	4.890	5.510		
2022-135	4	AB-CELL DY	115 ABBOTT C-D	121	4.421	0.134	3.02	4.160	4.690		
2022-135	5	BECTON D	137 B.C DXH	55	4.116	0.065	1.58	3.870	4.360		
2022-135	6	MR Mindray	145 BC-5390	45	4.488	0.062	1.37	4.220	4.760		
2022-135	7	DXH500 Ser	149 BC DXH 500	28	5.256	0.078	1.47	4.940	5.570		
2022-135	8	3 ST	84 ABBOTT C-D	37	5.561	0.111	2.00	5.230	5.890		
2022-135	8	3 ST	98 SYSMEX K-	11	5.525	0.045	0.82	5.190	5.860		
2022-135	8	3 ST	138 SY KX-21N	19	5.538	0.062	1.12	5.210	5.870		
2022-135	9	3 D	33 COULTER JT	12	5.723	0.084	1.47	5.380	6.070		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2022-135	9 3 D	120 COULTER		20	5.695	0.141	2.48	5.350	6.040		
550 HEMATOCRIT (HCT)		CLIA TEST ID #: 785	EVALUATION CRITERIA: TARGET VALUE 6 %								
2022-131	1 Sysmex CBC	127 SYSMEX XT		13	18.967	0.364	1.92	17.800	20.100		
2022-131	1 Sysmex CBC	132 SYSMEX XS		145	18.446	0.322	1.74	17.300	19.600		
2022-131	1 Sysmex CBC	141 SYSMEX XN		47	17.896	0.345	1.93	16.800	19.000		
2022-131	1 Sysmex CBC	152 Sysmex XN		71	17.901	0.331	1.85	16.800	19.000		
2022-131	2 ACT PENTRA	125 COULTER AC		131	38.482	0.758	1.97	36.200	40.800		
2022-131	2 ACT PENTRA	130 ABX PENTRA		27	38.815	0.753	1.94	36.500	41.100		
2022-131	3 ADVIA 120	116 ADVIA-120		16	36.794	0.853	2.32	34.600	39.000		
2022-131	4 AB-CELL DY	115 ABBOTT C-D		121	44.783	1.650	3.68	42.100	47.500		
2022-131	5 BECTON D	137 B.C DXH		55	20.902	0.369	1.76	19.600	22.200		
2022-131	6 MR Mindray	145 BC-5390		45	17.998	0.430	2.39	16.900	19.100		
2022-131	7 DXH500 Ser	149 BC DXH 500		28	42.670	0.756	1.77	40.100	45.200		
2022-131	8 3 ST	84 ABBOTT C-D		37	35.214	0.980	2.78	33.100	37.300		
2022-131	8 3 ST	98 SYSMEX K-		11	32.480	0.431	1.33	30.500	34.400		
2022-131	8 3 ST	138 SY KX-21N		19	32.624	0.515	1.58	30.700	34.600		
2022-131	9 3 D	33 COULTER JT		12	39.267	0.573	1.46	36.900	41.600		
2022-131	9 3 D	120 COULTER		20	39.010	1.068	2.74	36.700	41.400		
2022-132	1 Sysmex CBC	127 SYSMEX XT		13	53.285	0.930	1.74	50.100	56.500		
2022-132	1 Sysmex CBC	132 SYSMEX XS		145	53.094	0.990	1.87	49.900	56.300		
2022-132	1 Sysmex CBC	141 SYSMEX XN		47	52.546	1.341	2.55	49.400	55.700		
2022-132	1 Sysmex CBC	152 Sysmex XN		71	52.439	0.906	1.73	49.300	55.600		
2022-132	2 ACT PENTRA	125 COULTER AC		131	45.675	0.923	2.02	42.900	48.400		
2022-132	2 ACT PENTRA	130 ABX PENTRA		27	46.089	0.821	1.78	43.300	48.900		
2022-132	3 ADVIA 120	116 ADVIA-120		16	46.631	1.090	2.34	43.800	49.400		
2022-132	4 AB-CELL DY	115 ABBOTT C-D		121	37.353	1.524	4.08	35.100	39.600		
2022-132	5 BECTON D	137 B.C DXH		55	54.160	0.840	1.55	50.900	57.400		
2022-132	6 MR Mindray	145 BC-5390		45	48.602	1.200	2.47	45.700	51.500		
2022-132	7 DXH500 Ser	149 BC DXH 500		28	50.212	0.745	1.48	47.200	53.200		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-134	4	AB-CELL DY	115	ABBOTT C-D	121	15.565	0.450	2.89	14.600	16.500	
2022-134	5	BECTON D	137	B.C DXH	55	54.465	0.702	1.29	51.200	57.700	
2022-134	6	MR Mindray	145	BC-5390	45	48.537	1.187	2.45	45.600	51.400	
2022-134	7	DXH500 Ser	149	BC DXH 500	28	18.919	0.360	1.90	17.800	20.100	
2022-134	8	3 ST	84	ABBOTT C-D	37	18.308	0.440	2.40	17.200	19.400	
2022-134	8	3 ST	98	SYSMEX K-	11	17.320	0.325	1.88	16.300	18.400	
2022-134	8	3 ST	138	SY KX-21N	19	17.322	0.237	1.37	16.300	18.400	
2022-134	9	3 D	33	COULTER JT	12	17.067	0.352	2.06	16.000	18.100	
2022-134	9	3 D	120	COULTER	20	17.332	0.538	3.10	16.300	18.400	
550 HEMATOCRIT (HCT)			CLIA TEST ID #: 785		EVALUATION CRITERIA: TARGET VALUE 6 %						
2022-135	1	Sysmex CBC	127	SYSMEX XT	13	40.992	0.666	1.63	38.500	43.500	
2022-135	1	Sysmex CBC	132	SYSMEX XS	145	40.369	0.715	1.77	37.900	42.800	
2022-135	1	Sysmex CBC	141	SYSMEX XN	47	40.219	0.655	1.63	37.800	42.600	
2022-135	1	Sysmex CBC	152	Sysmex XN	71	39.996	0.711	1.78	37.600	42.400	
2022-135	2	ACT PENTRA	125	COULTER AC	131	45.561	0.844	1.85	42.800	48.300	
2022-135	2	ACT PENTRA	130	ABX PENTRA	27	46.015	0.912	1.98	43.300	48.800	
2022-135	3	ADVIA 120	116	ADVIA-120	16	46.631	1.253	2.69	43.800	49.400	
2022-135	4	AB-CELL DY	115	ABBOTT C-D	121	37.310	1.409	3.78	35.100	39.500	
2022-135	5	BECTON D	137	B.C DXH	55	38.805	0.633	1.63	36.500	41.100	
2022-135	6	MR Mindray	145	BC-5390	45	38.257	0.862	2.25	36.000	40.600	
2022-135	7	DXH500 Ser	149	BC DXH 500	28	50.185	0.906	1.80	47.200	53.200	
2022-135	8	3 ST	84	ABBOTT C-D	37	51.683	1.276	2.47	48.600	54.800	
2022-135	8	3 ST	98	SYSMEX K-	11	48.180	0.749	1.56	45.300	51.100	
2022-135	8	3 ST	138	SY KX-21N	19	48.233	0.666	1.38	45.300	51.100	
2022-135	9	3 D	33	COULTER JT	12	52.308	0.829	1.59	49.200	55.400	
2022-135	9	3 D	120	COULTER	20	52.565	1.490	2.83	49.400	55.700	
551 HEMOGLOBIN (HGB)			CLIA TEST ID #: 795		EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}						
2022-131	1	Sysmex CBC	127	SYSMEX XT	13	5.975	0.083	1.39	5.600	6.400	
2022-131	1	Sysmex CBC	132	SYSMEX XS	147	5.835	0.081	1.39	5.400	6.200	
2022-131	1	Sysmex CBC	141	SYSMEX XN	45	5.911	0.077	1.30	5.500	6.300	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-131	1	Sysmex CBC	152	Sysmex XN	71	5.910	0.061	1.03	5.500	6.300	
2022-131	2	ACT PENTRA	125	COULTER AC	131	13.788	0.189	1.37	12.800	14.800	
2022-131	2	ACT PENTRA	130	ABX PENTRA	27	13.959	0.173	1.24	13.000	14.900	
2022-131	3	ADVIA 120	116	ADVIA-120	16	13.569	0.289	2.13	12.600	14.500	
2022-131	4	AB-CELL DY	115	ABBOTT C-D	121	16.867	0.330	1.96	15.700	18.000	
2022-131	5	BECTON D	137	B.C DXH	55	6.551	0.095	1.45	6.100	7.000	
2022-131	6	MR Mindray	145	BC-5390	45	5.874	0.143	2.44	5.500	6.300	
2022-131	7	DXH500 Ser	149	BC DXH 500	27	14.838	0.139	0.94	13.800	15.900	
2022-131	8	3 ST	84	ABBOTT C-D	38	12.111	0.289	2.39	11.300	13.000	
2022-131	8	3 ST	98	SYSMEX K-	11	12.080	0.240	1.99	11.200	12.900	
2022-131	8	3 ST	138	SY KX-21N	19	12.000	0.176	1.47	11.200	12.800	
2022-131	9	3 D	33	COULTER JT	12	13.733	0.213	1.55	12.800	14.700	
2022-131	9	3 D	120	COULTER	20	13.490	0.257	1.90	12.500	14.400	
551	HEMOGLOBIN (HGB)		CLIA TEST ID #: 795			EVALUATION CRITERIA: TARGET VALUE	7 %	OR 2.00	{LOWER}		
2022-132	1	Sysmex CBC	127	SYSMEX XT	13	17.715	0.161	0.91	16.500	19.000	
2022-132	1	Sysmex CBC	132	SYSMEX XS	147	17.833	0.170	0.95	16.600	19.100	
2022-132	1	Sysmex CBC	141	SYSMEX XN	45	17.775	0.200	1.13	16.500	19.000	
2022-132	1	Sysmex CBC	152	Sysmex XN	71	17.761	0.135	0.76	16.500	19.000	
2022-132	2	ACT PENTRA	125	COULTER AC	131	16.396	0.232	1.42	15.200	17.500	
2022-132	2	ACT PENTRA	130	ABX PENTRA	27	16.670	0.176	1.06	15.500	17.800	
2022-132	3	ADVIA 120	116	ADVIA-120	16	17.275	0.336	1.95	16.100	18.500	
2022-132	4	AB-CELL DY	115	ABBOTT C-D	121	13.700	0.264	1.93	12.700	14.700	
2022-132	5	BECTON D	137	B.C DXH	55	16.900	0.183	1.08	15.700	18.100	
2022-132	6	MR Mindray	145	BC-5390	45	16.593	0.286	1.73	15.400	17.800	
2022-132	7	DXH500 Ser	149	BC DXH 500	27	17.512	0.187	1.07	16.300	18.700	
2022-132	8	3 ST	84	ABBOTT C-D	38	17.837	0.442	2.48	16.600	19.100	
2022-132	8	3 ST	98	SYSMEX K-	11	17.940	0.233	1.30	16.700	19.200	
2022-132	8	3 ST	138	SY KX-21N	19	17.894	0.204	1.14	16.600	19.100	
2022-132	9	3 D	33	COULTER JT	12	18.700	0.465	2.49	17.400	20.000	
2022-132	9	3 D	120	COULTER	20	18.300	0.485	2.65	17.000	19.600	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795	EVALUATION CRITERIA: TARGET VALUE	7 % OR 2.00	{LOWER}				
2022-133	1	127	Sysmex CBC SYSMEX XT	13	13.415	0.151	1.13	12.500	14.400
2022-133	1	132	Sysmex CBC SYSMEX XS	147	13.386	0.136	1.01	12.400	14.300
2022-133	1	141	Sysmex CBC SYSMEX XN	45	13.458	0.127	0.95	12.500	14.400
2022-133	1	152	Sysmex CBC Sysmex XN	71	13.407	0.092	0.69	12.500	14.300
2022-133	2	125	ACT PENTRA COULTER AC	131	6.495	0.132	2.03	6.000	7.000
2022-133	2	130	ACT PENTRA ABX PENTRA	27	6.433	0.090	1.40	6.000	6.900
2022-133	3	116	ADVIA 120 ADVIA-120	16	5.831	0.110	1.89	5.400	6.200
2022-133	4	115	AB-CELL DY ABBOTT C-D	121	16.793	0.368	2.19	15.600	18.000
2022-133	5	137	BECTON D B.C DXH	55	12.242	0.144	1.17	11.400	13.100
2022-133	6	145	MR Mindray BC-5390	45	12.872	0.198	1.54	12.000	13.800
2022-133	7	149	DXH500 Ser BC DXH 500	27	6.420	0.075	1.17	6.000	6.900
2022-133	8	84	3 ST ABBOTT C-D	38	6.384	0.180	2.82	5.900	6.800
2022-133	8	98	3 ST SYSMEX K-	11	6.230	0.100	1.61	5.800	6.700
2022-133	8	138	3 ST SY KX-21N	19	6.200	0.141	2.28	5.800	6.600
2022-133	9	33	3 D COULTER JT	12	5.758	0.150	2.60	5.400	6.200
2022-133	9	120	3 D COULTER	20	5.858	0.193	3.29	5.400	6.300
2022-134	1	127	Sysmex CBC SYSMEX XT	13	17.685	0.183	1.04	16.400	18.900
2022-134	1	132	Sysmex CBC SYSMEX XS	147	17.856	0.182	1.02	16.600	19.100
2022-134	1	141	Sysmex CBC SYSMEX XN	45	17.824	0.168	0.94	16.600	19.100
2022-134	1	152	Sysmex CBC Sysmex XN	71	17.782	0.115	0.65	16.500	19.000
2022-134	2	125	ACT PENTRA COULTER AC	131	6.495	0.110	1.69	6.000	7.000
2022-134	2	130	ACT PENTRA ABX PENTRA	27	6.430	0.094	1.45	6.000	6.900
2022-134	3	116	ADVIA 120 ADVIA-120	16	5.756	0.127	2.21	5.400	6.200
2022-134	4	115	AB-CELL DY ABBOTT C-D	121	5.944	0.180	3.03	5.500	6.400
2022-134	5	137	BECTON D B.C DXH	55	16.938	0.177	1.05	15.800	18.100
2022-134	6	145	MR Mindray BC-5390	45	16.598	0.289	1.74	15.400	17.800
2022-134	7	149	DXH500 Ser BC DXH 500	27	6.428	0.087	1.36	6.000	6.900
2022-134	8	84	3 ST ABBOTT C-D	38	6.366	0.177	2.77	5.900	6.800

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-134	8 3 ST	98 SYSMEX K-			11	6.180	0.133	2.15	5.700	6.600	
2022-134	8 3 ST	138 SY KX-21N			19	6.200	0.128	2.07	5.800	6.600	
2022-134	9 3 D	33 COULTER JT			12	5.733	0.131	2.29	5.300	6.100	
2022-134	9 3 D	120 COULTER			20	5.900	0.234	3.97	5.500	6.300	
551 HEMOGLOBIN (HGB)		CLIA TEST ID #: 795							EVALUATION CRITERIA: TARGET VALUE 7 % OR 2.00 {LOWER}		
2022-135	1 Sysmex CBC	127 SYSMEX XT			13	13.431	0.120	0.89	12.500	14.400	
2022-135	1 Sysmex CBC	132 SYSMEX XS			147	13.376	0.122	0.91	12.400	14.300	
2022-135	1 Sysmex CBC	141 SYSMEX XN			45	13.471	0.133	0.99	12.500	14.400	
2022-135	1 Sysmex CBC	152 Sysmex XN			71	13.428	0.086	0.64	12.500	14.400	
2022-135	2 ACT PENTRA	125 COULTER AC			131	16.381	0.232	1.41	15.200	17.500	
2022-135	2 ACT PENTRA	130 ABX PENTRA			27	16.674	0.186	1.11	15.500	17.800	
2022-135	3 ADVIA 120	116 ADVIA-120			16	17.231	0.355	2.06	16.000	18.400	
2022-135	4 AB-CELL DY	115 ABBOTT C-D			121	13.611	0.256	1.88	12.700	14.600	
2022-135	5 BECTON D	137 B.C DXH			55	12.253	0.145	1.18	11.400	13.100	
2022-135	6 MR Mindray	145 BC-5390			45	12.898	0.182	1.41	12.000	13.800	
2022-135	7 DXH500 Ser	149 BC DXH 500			27	17.600	0.185	1.05	16.400	18.800	
2022-135	8 3 ST	84 ABBOTT C-D			38	17.847	0.456	2.55	16.600	19.100	
2022-135	8 3 ST	98 SYSMEX K-			11	17.920	0.204	1.14	16.700	19.200	
2022-135	8 3 ST	138 SY KX-21N			19	17.883	0.211	1.18	16.600	19.100	
2022-135	9 3 D	33 COULTER JT			12	18.667	0.423	2.27	17.400	20.000	
2022-135	9 3 D	120 COULTER			20	18.365	0.543	2.96	17.100	19.700	
552 WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805							EVALUATION CRITERIA: TARGET VALUE 15 %		
2022-131	1 Sysmex CBC	127 SYSMEX XT			13	3.917	0.152	3.88	3.300	4.500	
2022-131	1 Sysmex CBC	132 SYSMEX XS			145	3.944	0.115	2.91	3.400	4.500	
2022-131	1 Sysmex CBC	141 SYSMEX XN			48	3.760	0.201	5.34	3.200	4.300	
2022-131	1 Sysmex CBC	152 Sysmex XN			70	3.407	0.106	3.10	2.900	3.900	
2022-131	2 ACT PENTRA	125 COULTER AC			131	8.004	0.289	3.61	6.800	9.200	
2022-131	2 ACT PENTRA	130 ABX PENTRA			27	7.748	0.264	3.41	6.600	8.900	
2022-131	3 ADVIA 120	116 ADVIA-120			16	7.607	0.184	2.42	6.500	8.700	
2022-131	4 AB-CELL DY	115 ABBOTT C-D			121	20.538	0.741	3.61	17.500	23.600	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-131	5	BECTON D	137 B.C DXH	55	4.096	0.237	5.78	3.500	4.700
2022-131	6	MR Mindray	145 BC-5390	45	3.402	0.085	2.49	2.900	3.900
2022-131	7	DXH500 Ser	149 BC DXH 500	28	7.415	0.170	2.30	6.300	8.500
2022-131	8	3 ST	84 ABBOTT C-D	37	8.151	0.543	6.66	6.900	9.400
2022-131	8	3 ST	98 SYSMEX K-	11	8.150	0.191	2.34	6.900	9.400
2022-131	8	3 ST	138 SY KX-21N	19	8.244	0.236	2.87	7.000	9.500
2022-131	9	3 D	33 COULTER JT	12	8.258	0.225	2.73	7.000	9.500
2022-131	9	3 D	120 COULTER	20	7.995	0.309	3.86	6.800	9.200
552 WHITE CELL COUNT(WBC)		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-132	1	Sysmex CBC	127 SYSMEX XT	13	20.185	0.758	3.76	17.200	23.200
2022-132	1	Sysmex CBC	132 SYSMEX XS	145	19.917	0.691	3.47	16.900	22.900
2022-132	1	Sysmex CBC	141 SYSMEX XN	48	20.602	0.462	2.24	17.500	23.700
2022-132	1	Sysmex CBC	152 Sysmex XN	70	19.916	0.443	2.22	16.900	22.900
2022-132	2	ACT PENTRA	125 COULTER AC	131	17.724	0.642	3.62	15.100	20.400
2022-132	2	ACT PENTRA	130 ABX PENTRA	27	17.293	0.498	2.88	14.700	19.900
2022-132	3	ADVIA 120	116 ADVIA-120	16	17.113	0.554	3.24	14.500	19.700
2022-132	4	AB-CELL DY	115 ABBOTT C-D	121	8.086	0.348	4.31	6.900	9.300
2022-132	5	BECTON D	137 B.C DXH	55	21.984	0.630	2.87	18.700	25.300
2022-132	6	MR Mindray	145 BC-5390	45	18.853	0.408	2.17	16.000	21.700
2022-132	7	DXH500 Ser	149 BC DXH 500	28	18.831	0.289	1.54	16.000	21.700
2022-132	8	3 ST	84 ABBOTT C-D	37	20.570	1.232	5.99	17.500	23.700
2022-132	8	3 ST	98 SYSMEX K-	11	20.660	0.427	2.07	17.600	23.800
2022-132	8	3 ST	138 SY KX-21N	19	20.883	0.546	2.61	17.800	24.000
2022-132	9	3 D	33 COULTER JT	12	22.167	0.721	3.25	18.800	25.500
2022-132	9	3 D	120 COULTER	20	21.045	0.875	4.16	17.900	24.200
2022-133	1	Sysmex CBC	127 SYSMEX XT	13	7.738	0.354	4.58	6.600	8.900
2022-133	1	Sysmex CBC	132 SYSMEX XS	145	7.495	0.463	6.17	6.400	8.600
2022-133	1	Sysmex CBC	141 SYSMEX XN	48	7.465	0.362	4.85	6.300	8.600
2022-133	1	Sysmex CBC	152 Sysmex XN	70	6.856	0.214	3.12	5.800	7.900

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 132 COMP BLOOD COUNT NEW

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2022-133	2	ACT PENTRA	125 COULTER AC	131	2.652	0.129	4.87	2.300	3.000
2022-133	2	ACT PENTRA	130 ABX PENTRA	27	2.585	0.076	2.92	2.200	3.000
2022-133	3	ADVIA 120	116 ADVIA-120	16	3.119	0.107	3.44	2.700	3.600
2022-133	4	AB-CELL DY	115 ABBOTT C-D	121	20.502	0.628	3.06	17.400	23.600
2022-133	5	BECTON D	137 B.C DXH	55	9.738	0.232	2.39	8.300	11.200
2022-133	6	MR Mindray	145 BC-5390	45	8.233	0.242	2.94	7.000	9.500
2022-133	7	DXH500 Ser	149 BC DXH 500	28	2.315	0.135	5.84	2.000	2.700
2022-133	8	3 ST	84 ABBOTT C-D	37	3.086	0.153	4.97	2.600	3.500
2022-133	8	3 ST	98 SYSMEX K-	11	2.930	0.119	4.05	2.500	3.400
2022-133	8	3 ST	138 SY KX-21N	19	2.933	0.075	2.54	2.500	3.400
2022-133	9	3 D	33 COULTER JT	12	2.092	0.155	7.42	1.800	2.400
2022-133	9	3 D	120 COULTER	20	2.265	0.115	5.09	1.900	2.600
552 WHITE CELL COUNT(WBC		CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %						
2022-134	1	Sysmex CBC	127 SYSMEX XT	13	19.931	0.896	4.50	16.900	22.900
2022-134	1	Sysmex CBC	132 SYSMEX XS	145	19.833	0.684	3.45	16.900	22.800
2022-134	1	Sysmex CBC	141 SYSMEX XN	48	20.560	0.459	2.23	17.500	23.600
2022-134	1	Sysmex CBC	152 Sysmex XN	70	19.900	0.474	2.38	16.900	22.900
2022-134	2	ACT PENTRA	125 COULTER AC	131	2.644	0.110	4.17	2.200	3.000
2022-134	2	ACT PENTRA	130 ABX PENTRA	27	2.574	0.093	3.60	2.200	3.000
2022-134	3	ADVIA 120	116 ADVIA-120	16	3.094	0.090	2.91	2.600	3.600
2022-134	4	AB-CELL DY	115 ABBOTT C-D	121	3.004	0.244	8.13	2.600	3.500
2022-134	5	BECTON D	137 B.C DXH	55	21.955	0.639	2.91	18.700	25.200
2022-134	6	MR Mindray	145 BC-5390	45	18.912	0.402	2.12	16.100	21.700
2022-134	7	DXH500 Ser	149 BC DXH 500	28	2.296	0.143	6.22	2.000	2.600
2022-134	8	3 ST	84 ABBOTT C-D	37	2.994	0.224	7.47	2.500	3.400
2022-134	8	3 ST	98 SYSMEX K-	11	2.920	0.117	3.99	2.500	3.400
2022-134	8	3 ST	138 SY KX-21N	19	2.906	0.103	3.53	2.500	3.300
2022-134	9	3 D	33 COULTER JT	12	2.067	0.137	6.65	1.800	2.400
2022-134	9	3 D	120 COULTER	20	2.200	0.148	6.74	1.900	2.500

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 132 COMP BLOOD COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
552	WHITE CELL COUNT(WBC	CLIA TEST ID #: 805	EVALUATION CRITERIA: TARGET VALUE 15 %							
2022-135	1	Sysmex CBC	127	SYSMEX XT	13	7.777	0.326	4.19	6.600	8.900
2022-135	1	Sysmex CBC	132	SYSMEX XS	145	7.463	0.487	6.53	6.300	8.600
2022-135	1	Sysmex CBC	141	SYSMEX XN	48	7.477	0.359	4.80	6.400	8.600
2022-135	1	Sysmex CBC	152	Sysmex XN	70	6.875	0.255	3.71	5.800	7.900
2022-135	2	ACT PENTRA	125	COULTER AC	131	17.671	0.607	3.43	15.000	20.300
2022-135	2	ACT PENTRA	130	ABX PENTRA	27	17.278	0.519	3.00	14.700	19.900
2022-135	3	ADVIA 120	116	ADVIA-120	16	16.894	0.739	4.37	14.400	19.400
2022-135	4	AB-CELL DY	115	ABBOTT C-D	121	7.958	0.273	3.43	6.800	9.200
2022-135	5	BECTON D	137	B.C DXH	55	9.713	0.252	2.60	8.300	11.200
2022-135	6	MR Mindray	145	BC-5390	45	8.230	0.199	2.42	7.000	9.500
2022-135	7	DXH500 Ser	149	BC DXH 500	28	18.904	0.326	1.73	16.100	21.700
2022-135	8	3 ST	84	ABBOTT C-D	37	20.443	1.123	5.49	17.400	23.500
2022-135	8	3 ST	98	SYSMEX K-	11	20.610	0.491	2.38	17.500	23.700
2022-135	8	3 ST	138	SY KX-21N	19	20.844	0.524	2.51	17.700	24.000
2022-135	9	3 D	33	COULTER JT	12	21.900	0.739	3.38	18.600	25.200
2022-135	9	3 D	120	COULTER	20	21.100	0.902	4.28	17.900	24.300

SPEC: 20 HEMATOLOGY		SUB: 70 GENERAL		GRP: 134 PLATELET COUNT NEW						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
553	PLATELET COUNT	CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-131	1	SYSMEX CBC	75	SYSMEX XT	13	58.583	5.852	9.99	44.000	73.000
2022-131	1	SYSMEX CBC	79	SYSMEX XS	146	54.138	3.375	6.23	41.000	68.000
2022-131	1	SYSMEX CBC	87	SYSMEX XN	47	49.087	2.628	5.35	37.000	61.000
2022-131	1	SYSMEX CBC	98	SYSMEX 350	69	49.174	3.153	6.41	37.000	61.000
2022-131	2	ACT5 PENTR	73	COULTER AC	128	250.984	14.103	5.62	188.000	314.000
2022-131	2	ACT5 PENTR	78	ABX PENTRA	27	245.778	8.612	3.50	184.000	307.000
2022-131	3	ADVIA 120	64	ADVIA-120	16	234.375	16.733	7.14	176.000	293.000

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2022-131	4	AB- CELL-D	63	ABBOTT C-D	119	514.462	24.363	4.74	386.000	643.000	
2022-131	5	BECTION D	83	B.C600,800	56	78.000	2.288	2.93	59.000	98.000	
2022-131	6	MR Mindray	91	BC-5390	45	53.256	3.321	6.24	40.000	67.000	
2022-131	8	3 ST	31	ABBOTT C-D	39	190.289	14.205	7.46	143.000	238.000	
2022-131	8	3 ST	39	SYSMEX K-	10	195.800	4.167	2.13	147.000	245.000	
2022-131	8	3 ST	84	KX21,300	21	197.737	10.422	5.27	148.000	247.000	
2022-131	9	3 D	50	COULT.JT,M	11	277.000	6.481	2.34	208.000	346.000	
2022-131	9	3 D	68	COULTERAcT	19	278.737	12.472	4.47	209.000	348.000	
2022-131	10	DxH	94	BC DXH 500	28	261.481	12.796	4.89	196.000	327.000	
553 PLATELET COUNT		CLIA TEST ID #: 815		EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-132	1	SYSMEX CBC	75	SYSMEX XT	13	386.846	36.015	9.31	290.000	484.000	
2022-132	1	SYSMEX CBC	79	SYSMEX XS	146	374.625	21.694	5.79	281.000	468.000	
2022-132	1	SYSMEX CBC	87	SYSMEX XN	47	406.106	15.656	3.86	305.000	508.000	
2022-132	1	SYSMEX CBC	98	SYSMEX 350	69	401.059	21.273	5.30	301.000	501.000	
2022-132	2	ACT5 PENTR	73	COULTER AC	128	477.134	23.961	5.02	358.000	596.000	
2022-132	2	ACT5 PENTR	78	ABX PENTRA	27	471.333	13.586	2.88	354.000	589.000	
2022-132	3	ADVIA 120	64	ADVIA-120	16	468.688	35.970	7.67	352.000	586.000	
2022-132	4	AB- CELL-D	63	ABBOTT C-D	119	278.729	16.372	5.87	209.000	348.000	
2022-132	5	BECTION D	83	B.C600,800	56	480.607	20.851	4.34	360.000	601.000	
2022-132	6	MR Mindray	91	BC-5390	45	538.698	15.664	2.91	404.000	673.000	
2022-132	8	3 ST	31	ABBOTT C-D	39	357.500	28.919	8.09	268.000	447.000	
2022-132	8	3 ST	39	SYSMEX K-	10	382.300	10.678	2.79	287.000	478.000	
2022-132	8	3 ST	84	KX21,300	21	385.526	16.554	4.29	289.000	482.000	
2022-132	9	3 D	50	COULT.JT,M	11	588.000	13.883	2.36	441.000	735.000	
2022-132	9	3 D	68	COULTERAcT	19	583.842	27.087	4.64	438.000	730.000	
2022-132	10	DxH	94	BC DXH 500	28	477.769	22.259	4.66	358.000	597.000	
2022-133	1	SYSMEX CBC	75	SYSMEX XT	13	195.769	17.833	9.11	147.000	245.000	
2022-133	1	SYSMEX CBC	79	SYSMEX XS	146	187.366	9.801	5.23	141.000	234.000	
2022-133	1	SYSMEX CBC	87	SYSMEX XN	47	195.149	6.520	3.34	146.000	244.000	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2022-133	1	SYSMEX CBC	98	SYSMEX 350	69	191.985	8.709	4.54	144.000	240.000	
2022-133	2	ACT5 PENTR	73	COULTER AC	128	69.252	4.287	6.19	52.000	87.000	
2022-133	2	ACT5 PENTR	78	ABX PENTRA	27	69.259	2.702	3.90	52.000	87.000	
2022-133	3	ADVIA 120	64	ADVIA-120	16	59.500	6.000	10.08	45.000	74.000	
2022-133	4	AB- CELL-D	63	ABBOTT C-D	119	514.735	25.523	4.96	386.000	643.000	
2022-133	5	BECTON D	83	B.C600,800	56	258.375	8.024	3.11	194.000	323.000	
2022-133	6	MR Mindray	91	BC-5390	45	259.545	10.860	4.18	195.000	324.000	
2022-133	8	3 ST	31	ABBOTT C-D	39	66.051	6.251	9.46	50.000	83.000	
2022-133	8	3 ST	39	SYSMEX K-	10	64.800	2.786	4.30	49.000	81.000	
2022-133	8	3 ST	84	KX21,300	21	66.053	4.123	6.24	50.000	83.000	
2022-133	9	3 D	50	COULT.JT,M	11	69.000	2.296	3.33	52.000	86.000	
2022-133	9	3 D	68	COULTERAcT	19	69.000	4.931	7.15	52.000	86.000	
2022-133	10	DxH	94	BC DXH 500	28	81.259	4.624	5.69	61.000	102.000	
553 PLATELET COUNT			CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %							
2022-134	1	SYSMEX CBC	75	SYSMEX XT	13	388.231	32.723	8.43	291.000	485.000	
2022-134	1	SYSMEX CBC	79	SYSMEX XS	146	373.368	26.265	7.03	280.000	467.000	
2022-134	1	SYSMEX CBC	87	SYSMEX XN	47	405.867	11.988	2.95	304.000	507.000	
2022-134	1	SYSMEX CBC	98	SYSMEX 350	69	400.662	22.069	5.51	300.000	501.000	
2022-134	2	ACT5 PENTR	73	COULTER AC	128	69.315	4.781	6.90	52.000	87.000	
2022-134	2	ACT5 PENTR	78	ABX PENTRA	27	70.111	4.067	5.80	53.000	88.000	
2022-134	3	ADVIA 120	64	ADVIA-120	16	57.000	5.232	9.18	43.000	71.000	
2022-134	4	AB- CELL-D	63	ABBOTT C-D	119	84.333	5.959	7.07	63.000	105.000	
2022-134	5	BECTON D	83	B.C600,800	56	457.964	14.236	3.11	343.000	572.000	
2022-134	6	MR Mindray	91	BC-5390	45	538.279	19.558	3.63	404.000	673.000	
2022-134	8	3 ST	31	ABBOTT C-D	39	64.385	6.134	9.53	48.000	80.000	
2022-134	8	3 ST	39	SYSMEX K-	10	65.200	4.045	6.20	49.000	82.000	
2022-134	8	3 ST	84	KX21,300	21	64.684	4.130	6.39	49.000	81.000	
2022-134	9	3 D	50	COULT.JT,M	11	66.455	1.876	2.82	50.000	83.000	
2022-134	9	3 D	68	COULTERAcT	19	69.632	4.158	5.97	52.000	87.000	
2022-134	10	DxH	94	BC DXH 500	28	78.462	5.055	6.44	59.000	98.000	

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 20 HEMATOLOGY

SUB: 70 GENERAL

GRP: 134 PLATELET COUNT NEW

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS			LABS	VALUE	DEVIATION	CV	LOW	HIGH
553	PLATELET COUNT	CLIA TEST ID #: 815	EVALUATION CRITERIA: TARGET VALUE 25 %								
2022-135	1	SYSMEX CBC	75	SYSMEX XT		13	196.615	15.380	7.82	147.000	246.000
2022-135	1	SYSMEX CBC	79	SYSMEX XS		146	187.490	9.473	5.05	141.000	234.000
2022-135	1	SYSMEX CBC	87	SYSMEX XN		47	195.064	6.356	3.26	146.000	244.000
2022-135	1	SYSMEX CBC	98	SYSMEX 350		69	192.881	8.410	4.36	145.000	241.000
2022-135	2	ACT5 PENTR	73	COULTER AC		128	476.165	24.086	5.06	357.000	595.000
2022-135	2	ACT5 PENTR	78	ABX PENTRA		27	469.519	16.033	3.41	352.000	587.000
2022-135	3	ADVIA 120	64	ADVIA-120		16	464.438	32.615	7.02	348.000	581.000
2022-135	4	AB- CELL-D	63	ABBOTT C-D		119	277.748	13.735	4.95	208.000	347.000
2022-135	5	BECTON D	83	B.C600,800		56	257.929	7.792	3.02	193.000	322.000
2022-135	6	MR Mindray	91	BC-5390		45	260.682	10.715	4.11	196.000	326.000
2022-135	8	3 ST	31	ABBOTT C-D		39	354.769	33.090	9.33	266.000	443.000
2022-135	8	3 ST	39	SYSMEX K-		10	384.800	15.497	4.03	289.000	481.000
2022-135	8	3 ST	84	KX21,300		21	388.895	11.956	3.07	292.000	486.000
2022-135	9	3 D	50	COULT.JT,M		11	575.273	17.205	2.99	431.000	719.000
2022-135	9	3 D	68	COULTERAcT		19	588.895	26.479	4.50	442.000	736.000
2022-135	10	DxH	94	BC DXH 500		28	471.185	18.401	3.91	353.000	589.000

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY			SUB: 120 GENERAL				GRP: 225 HELICOBACTER PYLORI					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
155 HELICOBACTER PYLORI												
2022-381	017	INST.V.ALF		002 002	002 002		002 - POSITIVE	22	22	22	100	
2022-382	017	INST.V.ALF		002 002	002 002		002 - POSITIVE	22	22	22	100	
2022-383	017	INST.V.ALF		001 001	001 001		001 - NEGATIVE	22	22	22	100	
2022-384	017	INST.V.ALF		002 002	002 002		002 - POSITIVE	22	22	22	100	
2022-385	017	INST.V.ALF		001 001	001 001		001 - NEGATIVE	22	22	22	100	

SPEC: 40 IMMUNOLOGY			SUB: 120 GENERAL				GRP: 220 ASOT, RA, MONO, CRP					
ANALYTE												
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
145 CRP - QUANTITATIVE												
			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 10.00 {LOWER}								
2022-351	34	DADE DIMEN			14	1.509	0.144	9.53	1.080	1.940		
2022-351	37	BECKMAN			12	1.249	0.142	11.41	0.820	1.680		
2022-351	37	BECKMAN			12	1.200	0.400	33.33	0.000	2.400		
2022-351	39	ROCHE COBA			12	1.309	0.056	4.30	1.140	1.480		
2022-351	42	ASI ARLING			27	1.200	0.400	33.33	0.000	2.400		
2022-351	42	ASI ARLING			27	2.308	0.876	37.95	0	4.930		
2022-351	47	VITROS 560			16	2.088	0.151	7.24	1.630	2.540		

Participant Summary

MONTH 4 OF YEAR 2022

SPEC: 40 IMMUNOLOGY

SUB: 120 GENERAL

GRP: 220 ASOT, RA, MONO, CRP

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
145	CRP - QUANTITATIVE	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR	10.00	{LOWER}			
2022-352	34	DADE DIMEN		14	0.072	0.055	75.39	0	0.240	
2022-352	37	BECKMAN		12	0.524	0.377	71.94	0	1.660	
2022-352	37	BECKMAN		12	0.200	0.346	173.21	0	1.240	
2022-352	39	ROCHE COBA		12	0.208	0.131	63.15	0	0.600	
2022-352	42	ASI ARLING		27	0.231	0.292	126.49	0	1.110	
2022-352	42	ASI ARLING		27	0.200	0.346	173.21	0	1.240	
2022-352	47	VITROS 560		16	0.500	0.000	0.00	0.500	0.500	
2022-353	34	DADE DIMEN		14	1.484	0.145	9.78	1.050	1.920	
2022-353	37	BECKMAN		12	1.295	0.084	6.46	1.040	1.550	
2022-353	37	BECKMAN		12	1.800	0.872	48.43	0	4.420	
2022-353	39	ROCHE COBA		12	1.228	0.046	3.78	1.090	1.370	
2022-353	42	ASI ARLING		27	1.800	0.872	48.43	0	4.420	
2022-353	42	ASI ARLING		27	2.815	1.728	61.36	0	8.000	
2022-353	47	VITROS 560		16	2.154	0.141	6.53	1.730	2.580	
2022-354	34	DADE DIMEN		14	0.162	0.043	26.69	0.030	0.290	
2022-354	37	BECKMAN		12	0.414	0.250	60.52	0	1.160	
2022-354	37	BECKMAN		12	0.200	0.346	173.21	0	1.240	
2022-354	39	ROCHE COBA		12	0.208	0.131	63.15	0	0.600	
2022-354	42	ASI ARLING		27	0.231	0.292	126.49	0	1.110	
2022-354	42	ASI ARLING		27	0.200	0.346	173.21	0	1.240	
2022-354	47	VITROS 560		16	0.500	0.000	0.00	0.500	0.500	
2022-355	34	DADE DIMEN		14	3.716	0.210	5.66	3.090	4.350	
2022-355	37	BECKMAN		12	2.400	0.800	33.33	0.000	4.800	
2022-355	37	BECKMAN		12	3.387	0.216	6.37	2.740	4.030	
2022-355	39	ROCHE COBA		12	3.400	0.160	4.71	2.920	3.880	
2022-355	42	ASI ARLING		27	2.400	0.800	33.33	0.000	4.800	

Participant Summary

MONTH 4 OF YEAR 2022

ANALYTE		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
SPEC: 40 IMMUNOLOGY SUB: 120 GENERAL GRP: 220 ASOT, RA, MONO, CRP										
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2022-355	42 ASI ARLING				27	2.815	0.995	35.35	0	5.800
2022-355	47 VITROS 560				16	4.763	0.162	3.41	4.280	5.250

SPE: 40 IMMUNOLOGY SUB: 120 GENERAL GRP: 220 ASOT, RA, MONO, CRP											
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
091 ANTISTREP.O-QUALITA.											
2022-351	384 ASI A.SCT.			001 001	001 001		002 - POSITIVE	30	3	27	0
2022-351	384 ASI A.SCT.			001 001	001 001		001 - NEGATIVE	30	27	27	100
2022-352	384 ASI A.SCT.			002 002	002 002		002 - POSITIVE	30	30	30	100
2022-353	384 ASI A.SCT.			001 001	001 001		001 - NEGATIVE	30	30	30	100
2022-354	384 ASI A.SCT.			001 001	001 001		001 - NEGATIVE	30	30	30	100
2022-355	384 ASI A.SCT.			001 001	001 001		001 - NEGATIVE	30	30	30	100
092 ANTISTREP.O-SEMI QUA											
2022-351	391 ASI SLIDE			014 014	014 014		014 - <100 IU/ml	11	10	10	100
2022-351	391 ASI SLIDE			014 014	014 014		016 - 200 IU/ml	11	1	10	0
2022-352	391 ASI SLIDE			015 019	015 019		018 - 800 IU/ml	11	2	11	100
2022-352	391 ASI SLIDE			015 019	015 019		017 - 400 IU/ml	11	9	11	100
2022-353	391 ASI SLIDE			014 014	014 014		014 - <100 IU/ml	11	11	11	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY			SUB: 120 GENERAL				GRP: 220 ASOT, RA, MONO, CRP				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
092 ANTISTREP.O-SEMI QUA											
2022-354	391	ASI SLIDE		014 014	014 014		014 - <100 IU/ml	11	11	11	100
2022-355	391	ASI SLIDE		014 014	014 014		014 - <100 IU/ml	11	11	11	100
103 INF. MONO- QUALITAT.											
2022-351	109	BIOKIT MON		002 002	002 002		002 - POSITIVE	41	41	41	100
2022-351	393	ASI A.SCT.		002 002	002 002		002 - POSITIVE	146	146	146	100
2022-351	394	TECO DIAG		002 002	002 002		002 - POSITIVE	25	25	25	100
2022-351	400	AIM MONO		002 002	002 002		002 - POSITIVE	11	11	11	100
2022-351	405	Acceava		002 002	002 002		002 - POSITIVE	14	14	14	100
2022-352	109	BIOKIT MON		001 001	001 001		001 - NEGATIVE	41	41	41	100
2022-352	393	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	146	146	146	100
2022-352	394	TECO DIAG		001 001	001 001		001 - NEGATIVE	25	25	25	100
2022-352	400	AIM MONO		001 001	001 001		001 - NEGATIVE	11	11	11	100
2022-352	405	Acceava		001 001	001 001		001 - NEGATIVE	14	14	14	100
2022-353	109	BIOKIT MON		001 001	001 001		001 - NEGATIVE	41	41	41	100
2022-353	393	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	146	146	146	100
2022-353	394	TECO DIAG		001 001	001 001		001 - NEGATIVE	25	25	25	100
2022-353	400	AIM MONO		001 001	001 001		001 - NEGATIVE	11	11	11	100
2022-353	405	Acceava		001 001	001 001		001 - NEGATIVE	14	14	14	100
2022-354	109	BIOKIT MON		001 001	001 001		001 - NEGATIVE	41	41	41	100
2022-354	393	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	146	146	146	100
2022-354	394	TECO DIAG		001 001	001 001		001 - NEGATIVE	25	25	25	100
2022-354	400	AIM MONO		001 001	001 001		001 - NEGATIVE	11	11	11	100
2022-354	405	Acceava		001 001	001 001		001 - NEGATIVE	14	14	14	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY

SUB: 120 GENERAL

GRP: 220 ASOT, RA, MONO, CRP

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
103 INF. MONO- QUALITAT.											
2022-355	109	BIOKIT MON		001 001	001 001		001 - NEGATIVE	41	41	41	100
2022-355	393	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	146	146	146	100
2022-355	394	TECO DIAG		001 001	001 001		001 - NEGATIVE	25	25	25	100
2022-355	400	AIM MONO		001 001	001 001		001 - NEGATIVE	11	11	11	100
2022-355	405	Acceava		001 001	001 001		001 - NEGATIVE	14	14	14	100
105 RF FACTOR(RA)-QUALI.											
2022-351	393	RHEUMAJET		002 002	002 002		002 - POSITIVE	24	24	24	100
2022-351	400	TECO DIAG.		002 002	002 002		002 - POSITIVE	52	52	52	100
2022-351	402	ASI A.SCT.		002 002	002 002		002 - POSITIVE	159	159	159	100
2022-351	406	AIM CRP RF		002 002	002 002		002 - POSITIVE	53	53	53	100
2022-351	408	STANBIO		002 002	002 002		002 - POSITIVE	28	28	28	100
2022-352	393	RHEUMAJET		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-352	400	TECO DIAG.		001 001	001 001		001 - NEGATIVE	52	52	52	100
2022-352	402	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	159	159	159	100
2022-352	406	AIM CRP RF		001 001	001 001		001 - NEGATIVE	53	53	53	100
2022-352	408	STANBIO		001 001	001 001		001 - NEGATIVE	28	28	28	100
2022-353	393	RHEUMAJET		002 002	002 002		002 - POSITIVE	24	24	24	100
2022-353	400	TECO DIAG.		002 002	002 002		002 - POSITIVE	52	52	52	100
2022-353	402	ASI A.SCT.		002 002	002 002		002 - POSITIVE	159	158	158	100
2022-353	402	ASI A.SCT.		002 002	002 002		001 - NEGATIVE	159	1	158	0
2022-353	406	AIM CRP RF		002 002	002 002		002 - POSITIVE	53	53	53	100
2022-353	408	STANBIO		002 002	002 002		002 - POSITIVE	28	28	28	100
2022-354	393	RHEUMAJET		001 001	001 001		001 - NEGATIVE	24	23	23	100
2022-354	393	RHEUMAJET		001 001	001 001		002 - POSITIVE	24	1	23	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY

SUB: 120 GENERAL

GRP: 220 ASOT, RA, MONO, CRP

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-354	400	TECO DIAG.		001 001	001 001		001 - NEGATIVE	52	52	52	100
2022-354	402	ASI A.SCT.		001 001	001 001		002 - POSITIVE	159	5	154	0
2022-354	402	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	159	154	154	100
2022-354	406	AIM CRP RF		001 001	001 001		001 - NEGATIVE	53	53	53	100
2022-354	408	STANBIO		001 001	001 001		001 - NEGATIVE	28	27	27	100
2022-354	408	STANBIO		001 001	001 001		002 - POSITIVE	28	1	27	0
105 RF FACTOR(RA)-QUALI.											
2022-355	393	RHEUMAJET		001 001	001 001		002 - POSITIVE	24	1	23	0
2022-355	393	RHEUMAJET		001 001	001 001		001 - NEGATIVE	24	23	23	100
2022-355	400	TECO DIAG.		001 001	001 001		001 - NEGATIVE	52	52	52	100
2022-355	402	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	159	147	147	100
2022-355	402	ASI A.SCT.		001 001	001 001		002 - POSITIVE	159	12	147	0
2022-355	406	AIM CRP RF		001 001	001 001		001 - NEGATIVE	53	52	52	100
2022-355	406	AIM CRP RF		001 001	001 001		002 - POSITIVE	53	1	52	0
2022-355	408	STANBIO		001 001	001 001		001 - NEGATIVE	28	27	27	100
2022-355	408	STANBIO		001 001	001 001		002 - POSITIVE	28	1	27	0
106 RF FAC(RA)-SEMI QUAN											
2022-351	393	RHEUMAJET		002 006	004 008		007 - 264-640 IU	11	1	11	100
2022-351	393	RHEUMAJET		002 006	004 008		004 - 40-80 IU/m	11	5	11	100
2022-351	393	RHEUMAJET		002 006	004 008		006 - 136-320 IU	11	1	11	100
2022-351	393	RHEUMAJET		002 006	004 008		003 - 24-40 IU/m	11	1	11	100
2022-351	393	RHEUMAJET		002 006	004 008		005 - 72-160 IU	11	3	11	100
2022-351	407	ASI SLIDE		004 008	004 008		005 - 72-160 IU	31	4	29	100
2022-351	407	ASI SLIDE		004 008	004 008		007 - 264-640 IU	31	12	29	100
2022-351	407	ASI SLIDE		004 008	004 008		003 - 24-40 IU/m	31	2	29	0
2022-351	407	ASI SLIDE		004 008	004 008		006 - 136-320 IU	31	13	29	100
2022-352	393	RHEUMAJET		001 001	001 001		001 - <8-20 IU/m	11	11	11	100
2022-352	407	ASI SLIDE		001 001	001 001		001 - <8-20 IU/m	31	31	31	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY		SUB: 120 GENERAL				GRP: 220 ASOT, RA, MONO, CRP						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
106 RF FAC(RA)-SEMI QUAN												
2022-353	393	RHEUMAJET		003	007	004	008	005 - 72-160 IU	11	4	11	100
2022-353	393	RHEUMAJET		003	007	004	008	004 - 40-80 IU/m	11	4	11	100
2022-353	393	RHEUMAJET		003	007	004	008	007 - 264-640 IU	11	2	11	100
2022-353	393	RHEUMAJET		003	007	004	008	006 - 136-320 IU	11	1	11	100
2022-353	407	ASI SLIDE		005	009	004	008	003 - 24-40 IU/m	31	1	30	0
2022-353	407	ASI SLIDE		005	009	004	008	005 - 72-160 IU	31	3	30	100
2022-353	407	ASI SLIDE		005	009	004	008	004 - 40-80 IU/m	31	1	30	100
2022-353	407	ASI SLIDE		005	009	004	008	007 - 264-640 IU	31	16	30	100
2022-353	407	ASI SLIDE		005	009	004	008	008 - 520-1280	31	1	30	100
2022-353	407	ASI SLIDE		005	009	004	008	006 - 136-320 IU	31	9	30	100
2022-354	393	RHEUMAJET		001	001	001	001	001 - <8-20 IU/m	11	10	10	100
2022-354	393	RHEUMAJET		001	001	001	001	002 - 8-20 IU/ml	11	1	10	0
2022-354	407	ASI SLIDE		001	001	001	001	002 - 8-20 IU/ml	31	3	28	0
2022-354	407	ASI SLIDE		001	001	001	001	001 - <8-20 IU/m	31	28	28	100
2022-355	393	RHEUMAJET		001	001	001	001	002 - 8-20 IU/ml	11	2	9	0
2022-355	393	RHEUMAJET		001	001	001	001	001 - <8-20 IU/m	11	9	9	100
2022-355	407	ASI SLIDE		001	001	001	001	002 - 8-20 IU/ml	31	4	27	0
2022-355	407	ASI SLIDE		001	001	001	001	001 - <8-20 IU/m	31	27	27	100
144 CRP- QUALITATIVE												
2022-351	026	ASI A.SCT.		002	002	002	002	002 - POSITIVE	137	137	137	100
2022-351	030	TECO DIAG.		002	002	002	002	002 - POSITIVE	39	38	38	100
2022-351	030	TECO DIAG.		002	002	002	002	001 - NEGATIVE	39	1	38	0
2022-351	036	AIM CRP RF		002	002	002	002	002 - POSITIVE	45	45	45	100
2022-351	041	STANBIO		002	002	002	002	002 - POSITIVE	16	16	16	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY		SUB: 120 GENERAL				GRP: 220 ASOT, RA, MONO, CRP						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
144 CRP- QUALITATIVE												
2022-352	026	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	137	134	134	100	
2022-352	026	ASI A.SCT.		001 001	001 001		002 - POSITIVE	137	3	134	0	
2022-352	030	TECO DIAG.		001 001	001 001		001 - NEGATIVE	39	39	39	100	
2022-352	036	AIM CRP RF		001 001	001 001		001 - NEGATIVE	45	44	44	100	
2022-352	036	AIM CRP RF		001 001	001 001		002 - POSITIVE	45	1	44	0	
2022-352	041	STANBIO		001 001	001 001		001 - NEGATIVE	16	16	16	100	
2022-353	026	ASI A.SCT.		002 002	002 002		002 - POSITIVE	137	137	137	100	
2022-353	030	TECO DIAG.		002 002	002 002		002 - POSITIVE	39	39	39	100	
2022-353	036	AIM CRP RF		002 002	002 002		002 - POSITIVE	45	45	45	100	
2022-353	041	STANBIO		002 002	002 002		002 - POSITIVE	16	16	16	100	
2022-354	026	ASI A.SCT.		001 001	001 001		001 - NEGATIVE	137	137	137	100	
2022-354	030	TECO DIAG.		001 001	001 001		001 - NEGATIVE	39	39	39	100	
2022-354	036	AIM CRP RF		001 001	001 001		001 - NEGATIVE	45	45	45	100	
2022-354	041	STANBIO		001 001	001 001		001 - NEGATIVE	16	16	16	100	
2022-355	026	ASI A.SCT.		002 002	002 002		001 - NEGATIVE	137	16	121	0	
2022-355	026	ASI A.SCT.		002 002	002 002		002 - POSITIVE	137	121	121	100	
2022-355	030	TECO DIAG.		002 002	002 002		002 - POSITIVE	39	38	38	100	
2022-355	030	TECO DIAG.		002 002	002 002		001 - NEGATIVE	39	1	38	0	
2022-355	036	AIM CRP RF		002 002	002 002		002 - POSITIVE	45	43	43	100	
2022-355	036	AIM CRP RF		002 002	002 002		001 - NEGATIVE	45	2	43	0	
2022-355	041	STANBIO		002 002	002 002		002 - POSITIVE	16	16	16	100	

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 120 GENERAL				GRP: 230 HBsAG, ANTI HBC, HIV				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
093 ANTI-HUMAN IMM. (HIV)												
2022-211	055	ALERE DETE		001 001	001 001		001 - NEG/NR	30	30	30	100	
2022-212	055	ALERE DETE		002 002	002 002		002 - POS/R	30	30	30	100	
2022-213	055	ALERE DETE		002 002	002 002		002 - POS/R	30	30	30	100	
2022-214	055	ALERE DETE		001 001	001 001		001 - NEG/NR	30	30	30	100	
2022-215	055	ALERE DETE		001 001	001 001		001 - NEG/NR	30	30	30	100	

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 120 GENERAL				GRP: 248 COVID-19 CORONAVIRUS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
554 COVID-19 CORONAVIRUS												
2022-272	001 IgM	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100	
2022-272	001 IgM	002 HEALGEN		002 002	002 002		002 - Positive	299	292	292	100	
2022-272	001 IgM	002 HEALGEN		002 002	002 002		001 - Negative	299	7	292	0	
2022-272	001 IgM	007 RIGHT SIGN		002 002	002 002		001 - Negative	103	2	101	0	
2022-272	001 IgM	007 RIGHT SIGN		002 002	002 002		002 - Positive	103	101	101	100	
2022-272	001 IgM	016 CLARITY		002 002	002 002		002 - Positive	61	60	60	100	
2022-272	001 IgM	016 CLARITY		002 002	002 002		001 - Negative	61	1	60	0	
2022-272	002 IgG	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100	
2022-272	002 IgG	002 HEALGEN		002 002	002 002		002 - Positive	300	300	300	100	
2022-272	002 IgG	007 RIGHT SIGN		002 002	002 002		002 - Positive	103	103	103	100	
2022-272	002 IgG	016 CLARITY		002 002	002 002		002 - Positive	61	61	61	100	
2022-272	002 IgG	020 PREMIER		002 002	002 002		002 - Positive	10	10	10	100	
2022-273	001 IgM	001 CORONACHEC		001 001	001 001		001 - Negative	13	13	13	100	
2022-273	001 IgM	002 HEALGEN		001 001	001 001		001 - Negative	299	299	299	100	
2022-273	001 IgM	007 RIGHT SIGN		001 001	001 001		001 - Negative	103	102	102	100	
2022-273	001 IgM	007 RIGHT SIGN		001 001	001 001		002 - Positive	103	1	102	0	
2022-273	001 IgM	016 CLARITY		001 001	001 001		001 - Negative	61	61	61	100	
2022-273	001 IgM	020 PREMIER		001 001	001 001		001 - Negative	10	10	10	100	
2022-273	002 IgG	001 CORONACHEC		001 001	001 001		001 - Negative	13	13	13	100	
2022-273	002 IgG	002 HEALGEN		001 001	001 001		001 - Negative	298	298	298	100	
2022-273	002 IgG	007 RIGHT SIGN		001 001	001 001		002 - Positive	103	1	102	0	
2022-273	002 IgG	007 RIGHT SIGN		001 001	001 001		001 - Negative	103	102	102	100	
2022-273	002 IgG	016 CLARITY		001 001	001 001		001 - Negative	61	61	61	100	
2022-273	002 IgG	020 PREMIER		001 001	001 001		001 - Negative	10	10	10	100	
2022-274	001 IgM	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100	
2022-274	001 IgM	002 HEALGEN		002 002	002 002		002 - Positive	298	293	293	100	

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY

SUB: 120 GENERAL

GRP: 248 COVID-19 CORONAVIRUS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-274	001 IgM	002 HEALGEN		002 002	002 002		001 - Negative	298	5	293	0
2022-274	001 IgM	007 RIGHT SIGN		002 002	002 002		002 - Positive	103	102	102	100
2022-274	001 IgM	007 RIGHT SIGN		002 002	002 002		001 - Negative	103	1	102	0
2022-274	001 IgM	016 CLARITY		002 002	002 002		002 - Positive	61	61	61	100
2022-274	001 IgM	020 PREMIER		002 002	002 002		002 - Positive	10	10	10	100
2022-274	002 IgG	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100
2022-274	002 IgG	002 HEALGEN		002 002	002 002		002 - Positive	300	299	299	100
2022-274	002 IgG	002 HEALGEN		002 002	002 002		001 - Negative	300	1	299	0
2022-274	002 IgG	007 RIGHT SIGN		002 002	002 002		002 - Positive	103	102	102	100
2022-274	002 IgG	007 RIGHT SIGN		002 002	002 002		001 - Negative	103	1	102	0
2022-274	002 IgG	016 CLARITY		002 002	002 002		002 - Positive	60	60	60	100
2022-274	002 IgG	020 PREMIER		002 002	002 002		002 - Positive	10	10	10	100
554 COVID-19 CORONAVIRUS											
2022-275	001 IgM	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100
2022-275	001 IgM	002 HEALGEN		002 002	002 002		002 - Positive	300	293	293	100
2022-275	001 IgM	002 HEALGEN		002 002	002 002		001 - Negative	300	7	293	0
2022-275	001 IgM	007 RIGHT SIGN		002 002	002 002		002 - Positive	102	102	102	100
2022-275	001 IgM	016 CLARITY		002 002	002 002		001 - Negative	61	1	60	0
2022-275	001 IgM	016 CLARITY		002 002	002 002		002 - Positive	61	60	60	100
2022-275	001 IgM	020 PREMIER		002 002	002 002		002 - Positive	10	10	10	100
2022-275	002 IgG	001 CORONACHEC		002 002	002 002		002 - Positive	13	13	13	100
2022-275	002 IgG	002 HEALGEN		002 002	002 002		002 - Positive	298	298	298	100
2022-275	002 IgG	007 RIGHT SIGN		002 002	002 002		002 - Positive	104	104	104	100
2022-275	002 IgG	016 CLARITY		002 002	002 002		002 - Positive	61	61	61	100
2022-275	002 IgG	020 PREMIER		002 002	002 002		002 - Positive	10	10	10	100

SPE: 40 IMMUNOLOGY

SUB: 130 SYPHILIS SEROLOGY

GRP: 250 SYPHILIS SEROLOGY

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 130 SYPHILIS SEROLOGY				GRP: 250 SYPHILIS SEROLOGY								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
109 SYPHILLIS SERO.-QUAL																
2022-321	002	RPR	028	BIOKIT-RPR			004	004	004	004	004	- React RPR	26	26	26	100
2022-321	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- NR Non Rea	84	1	83	0
2022-321	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- React RPR	84	83	83	100
2022-321	002	RPR	033	ASI			004	004	004	004	004	- React RPR	489	488	488	100
2022-321	002	RPR	033	ASI			004	004	004	004	004	- WR Weakly	489	1	488	0
2022-321	002	RPR	040	TECO DIAG.			004	004	004	004	004	- React RPR	64	64	64	100
2022-321	002	RPR	053	AIM RPR			004	004	004	004	004	- React RPR	76	76	76	100
2022-321	002	RPR	057	Germain La			004	004	004	004	004	- React RPR	23	23	23	100
2022-322	002	RPR	028	BIOKIT-RPR			004	004	004	004	004	- React RPR	26	26	26	100
2022-322	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- React RPR	84	83	83	100
2022-322	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- NR Non Rea	84	1	83	0
2022-322	002	RPR	033	ASI			004	004	004	004	004	- React RPR	489	489	489	100
2022-322	002	RPR	040	TECO DIAG.			004	004	004	004	004	- React RPR	64	64	64	100
2022-322	002	RPR	053	AIM RPR			004	004	004	004	004	- React RPR	76	76	76	100
2022-322	002	RPR	057	Germain La			004	004	004	004	004	- React RPR	23	23	23	100
2022-323	002	RPR	028	BIOKIT-RPR			004	004	004	004	004	- React RPR	26	26	26	100
2022-323	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- React RPR	84	82	82	100
2022-323	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- NR Non Rea	84	1	82	0
2022-323	002	RPR	030	IMMUNOSTIC			004	004	004	004	004	- WR Weakly	84	1	82	0
2022-323	002	RPR	033	ASI			004	004	004	004	004	- React RPR	489	488	488	100
2022-323	002	RPR	033	ASI			004	004	004	004	004	- NR Non Rea	489	1	488	0
2022-323	002	RPR	040	TECO DIAG.			004	004	004	004	004	- React RPR	64	64	64	100
2022-323	002	RPR	053	AIM RPR			004	004	004	004	004	- React RPR	76	76	76	100
2022-323	002	RPR	057	Germain La			004	004	004	004	004	- React RPR	23	23	23	100
2022-324	002	RPR	028	BIOKIT-RPR			001	001	001	001	001	- NR Non Rea	26	26	26	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 130 SYPHILLIS SEROLOGY				GRP: 250 SYPHILLIS SEROLOGY			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-324	002 RPR	030 IMMUNOSTIC		001 001	001 001		001 - NR Non Rea	84	83	83	100
2022-324	002 RPR	030 IMMUNOSTIC		001 001	001 001		004 - React RPR	84	1	83	0
2022-324	002 RPR	033 ASI		001 001	001 001		001 - NR Non Rea	489	489	489	100
2022-324	002 RPR	040 TECO DIAG.		001 001	001 001		001 - NR Non Rea	64	64	64	100
2022-324	002 RPR	053 AIM RPR		001 001	001 001		001 - NR Non Rea	76	76	76	100
2022-324	002 RPR	057 Germain La		001 001	001 001		001 - NR Non Rea	23	23	23	100
109 SYPHILLIS SERO.-QUAL											
2022-325	002 RPR	028 BLOKIT-RPR		001 001	001 001		001 - NR Non Rea	26	26	26	100
2022-325	002 RPR	030 IMMUNOSTIC		001 001	001 001		001 - NR Non Rea	84	83	83	100
2022-325	002 RPR	030 IMMUNOSTIC		001 001	001 001		004 - React RPR	84	1	83	0
2022-325	002 RPR	033 ASI		001 001	001 001		001 - NR Non Rea	489	488	488	100
2022-325	002 RPR	033 ASI		001 001	001 001		004 - React RPR	489	1	488	0
2022-325	002 RPR	040 TECO DIAG.		001 001	001 001		001 - NR Non Rea	64	64	64	100
2022-325	002 RPR	053 AIM RPR		001 001	001 001		001 - NR Non Rea	76	76	76	100
2022-325	002 RPR	057 Germain La		001 001	001 001		001 - NR Non Rea	23	23	23	100
110 SYPHILLIS SERO-QUANT											
2022-321	002 RPR	028 BLOKIT-RPR		004 006	004 006		005 - R- 4 DILS.	20	15	20	100
2022-321	002 RPR	028 BLOKIT-RPR		004 006	004 006		006 - R- 8 DILS.	20	4	20	100
2022-321	002 RPR	028 BLOKIT-RPR		004 006	004 006		004 - R- 2 DILS.	20	1	20	100
2022-321	002 RPR	030 IMMUNOSTIC		004 006	004 006		004 - R- 2 DILS.	25	4	25	100
2022-321	002 RPR	030 IMMUNOSTIC		004 006	004 006		005 - R- 4 DILS.	25	16	25	100
2022-321	002 RPR	030 IMMUNOSTIC		004 006	004 006		006 - R- 8 DILS.	25	5	25	100
2022-321	002 RPR	033 ASI		004 006	004 006	004 006	007 - R- 16 DILS	230	2	226	0
2022-321	002 RPR	033 ASI		004 006	004 006	004 006	005 - R- 4 DILS.	230	143	226	100
2022-321	002 RPR	033 ASI		004 006	004 006	004 006	006 - R- 8 DILS.	230	60	226	100
2022-321	002 RPR	033 ASI		004 006	004 006	004 006	003 - R- 1 DIL.	230	2	226	0
2022-321	002 RPR	033 ASI		004 006	004 006	004 006	004 - R- 2 DILS.	230	23	226	100
2022-321	002 RPR	040 TECO DIAG.		004 006	004 006		005 - R- 4 DILS.	16	8	16	100
2022-321	002 RPR	040 TECO DIAG.		004 006	004 006		004 - R- 2 DILS.	16	8	16	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 130 SYPHILLIS SEROLOGY				GRP: 250 SYPHILLIS SEROLOGY										
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE		PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-321	002	RPR	053	AIM RPR			004	006	004	006			005 - R- 4 DILS.	15	8	15	100	
2022-321	002	RPR	053	AIM RPR			004	006	004	006			006 - R- 8 DILS.	15	1	15	100	
2022-321	002	RPR	053	AIM RPR			004	006	004	006			004 - R- 2 DILS.	15	6	15	100	
110 SYPHILLIS SERO-QUANT																		
2022-322	002	RPR	028	BIOKIT-RPR			004	006	004	006			005 - R- 4 DILS.	20	12	18	100	
2022-322	002	RPR	028	BIOKIT-RPR			004	006	004	006			006 - R- 8 DILS.	20	1	18	100	
2022-322	002	RPR	028	BIOKIT-RPR			004	006	004	006			004 - R- 2 DILS.	20	5	18	100	
2022-322	002	RPR	028	BIOKIT-RPR			004	006	004	006			003 - R- 1 DIL.	20	2	18	0	
2022-322	002	RPR	030	IMMUNOSTIC			004	006	004	006			005 - R- 4 DILS.	25	17	25	100	
2022-322	002	RPR	030	IMMUNOSTIC			004	006	004	006			004 - R- 2 DILS.	25	8	25	100	
2022-322	002	RPR	033	ASI			004	006	004	006	004	006	005 - R- 4 DILS.	230	178	229	100	
2022-322	002	RPR	033	ASI			004	006	004	006	004	006	006 - R- 8 DILS.	230	26	229	100	
2022-322	002	RPR	033	ASI			004	006	004	006	004	006	003 - R- 1 DIL.	230	1	229	0	
2022-322	002	RPR	033	ASI			004	006	004	006	004	006	004 - R- 2 DILS.	230	25	229	100	
2022-322	002	RPR	040	TECO DIAG.			003	005	004	006			004 - R- 2 DILS.	16	9	16	100	
2022-322	002	RPR	040	TECO DIAG.			003	005	004	006			005 - R- 4 DILS.	16	6	16	100	
2022-322	002	RPR	040	TECO DIAG.			003	005	004	006			006 - R- 8 DILS.	16	1	16	100	
2022-322	002	RPR	053	AIM RPR			004	006	004	006			005 - R- 4 DILS.	15	8	15	100	
2022-322	002	RPR	053	AIM RPR			004	006	004	006			006 - R- 8 DILS.	15	1	15	100	
2022-322	002	RPR	053	AIM RPR			004	006	004	006			004 - R- 2 DILS.	15	6	15	100	
2022-323	002	RPR	028	BIOKIT-RPR			004	006	004	006			006 - R- 8 DILS.	20	5	20	100	
2022-323	002	RPR	028	BIOKIT-RPR			004	006	004	006			005 - R- 4 DILS.	20	10	20	100	
2022-323	002	RPR	028	BIOKIT-RPR			004	006	004	006			004 - R- 2 DILS.	20	5	20	100	
2022-323	002	RPR	030	IMMUNOSTIC			004	006	004	006			004 - R- 2 DILS.	25	4	24	100	
2022-323	002	RPR	030	IMMUNOSTIC			004	006	004	006			005 - R- 4 DILS.	25	17	24	100	
2022-323	002	RPR	030	IMMUNOSTIC			004	006	004	006			006 - R- 8 DILS.	25	3	24	100	
2022-323	002	RPR	030	IMMUNOSTIC			004	006	004	006			002 - WR- 0 DIL.	25	1	24	0	
2022-323	002	RPR	033	ASI			004	006	004	006	004	006	003 - R- 1 DIL.	230	1	228	0	

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 40 IMMUNOLOGY				SUB: 130 SYPHILIS SEROLOGY				GRP: 250 SYPHILIS SEROLOGY									
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH		COMMER LOW/HIGH		REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-323	002	RPR	033	ASI			004	006	004	006	004	006	004 - R- 2 DILS.	230	19	228	100
2022-323	002	RPR	033	ASI			004	006	004	006	004	006	007 - R- 16 DILS	230	1	228	0
2022-323	002	RPR	033	ASI			004	006	004	006	004	006	006 - R- 8 DILS.	230	65	228	100
2022-323	002	RPR	033	ASI			004	006	004	006	004	006	005 - R- 4 DILS.	230	144	228	100
2022-323	002	RPR	040	TECO DIAG.			003	005	004	006			005 - R- 4 DILS.	16	4	16	100
2022-323	002	RPR	040	TECO DIAG.			003	005	004	006			006 - R- 8 DILS.	16	1	16	100
2022-323	002	RPR	040	TECO DIAG.			003	005	004	006			003 - R- 1 DIL.	16	1	16	100
2022-323	002	RPR	040	TECO DIAG.			003	005	004	006			004 - R- 2 DILS.	16	10	16	100
2022-323	002	RPR	053	AIM RPR			004	006	004	006			005 - R- 4 DILS.	15	7	14	100
2022-323	002	RPR	053	AIM RPR			004	006	004	006			006 - R- 8 DILS.	15	3	14	100
2022-323	002	RPR	053	AIM RPR			004	006	004	006			004 - R- 2 DILS.	15	4	14	100
2022-323	002	RPR	053	AIM RPR			004	006	004	006			007 - R- 16 DILS	15	1	14	0
110 SYPHILLIS SERO-QUANT																	
2022-324	002	RPR	028	BIOKIT-RPR			001	001	001	001			001 - NR	20	20	20	100
2022-324	002	RPR	030	IMMUNOSTIC			001	001	001	001			001 - NR	25	25	25	100
2022-324	002	RPR	033	ASI			001	001	001	001	001	001	001 - NR	230	230	230	100
2022-324	002	RPR	040	TECO DIAG.			001	001	001	001			001 - NR	16	16	16	100
2022-324	002	RPR	053	AIM RPR			001	001	001	001			001 - NR	15	15	15	100
2022-325	002	RPR	028	BIOKIT-RPR			001	001	001	001			001 - NR	20	20	20	100
2022-325	002	RPR	030	IMMUNOSTIC			001	001	001	001			001 - NR	25	25	25	100
2022-325	002	RPR	033	ASI			001	001	001	001	001	001	004 - R- 2 DILS.	230	1	229	0
2022-325	002	RPR	033	ASI			001	001	001	001	001	001	001 - NR	230	229	229	100
2022-325	002	RPR	040	TECO DIAG.			001	001	001	001			001 - NR	16	16	16	100
2022-325	002	RPR	053	AIM RPR			001	001	001	001			001 - NR	15	15	15	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY		SUB: 140 BACTERIOLOGY				GRP: 260 BACTER. -GRAM STAIN					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
111 BACTER. GRAM STAIN											
2022-221				004 004	004 004		002 - GRAM POS B	79	1	77	0
2022-221				004 004	004 004		003 - GRAM NEG C	79	1	77	0
2022-221				004 004	004 004		004 - GRAM POS C	79	77	77	100
2022-222				001 001	001 001		003 - GRAM NEG C	79	2	73	0
2022-222				001 001	001 001		005 - GRAM NEG C	79	4	73	0
2022-222				001 001	001 001		001 - GRAM NEG B	79	73	73	100
2022-223				001 001	001 001		003 - GRAM NEG C	79	2	73	0
2022-223				001 001	001 001		002 - GRAM POS B	79	1	73	0
2022-223				001 001	001 001		001 - GRAM NEG B	79	73	73	100
2022-223				001 001	001 001		005 - GRAM NEG C	79	3	73	0
2022-224				004 004	004 004		002 - GRAM POS B	79	1	78	0
2022-224				004 004	004 004		004 - GRAM POS C	79	78	78	100
2022-225				001 001	001 001		002 - GRAM POS B	79	2	74	0
2022-225				001 001	001 001		001 - GRAM NEG B	79	74	74	100
2022-225				001 001	001 001		005 - GRAM NEG C	79	1	74	0
2022-225				001 001	001 001		003 - GRAM NEG C	79	2	74	0
SPE: 50 MICROBIOLOGY		SUB: 140 BACTERIOLOGY				GRP: 270 BACTERIOLOGY IDENT.					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
112 BACTER.-IDENTIFICAT.											
2022-241	001 AEROBIC	032 MICROSCAN			110 110		110 - Lister. mo	24	23	23	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 140 BACTERIOLOGY

GRP: 270 BACTERIOLOGY IDENT.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-241	001 AEROBIC	032 MICROSCAN			110 110		198 - Strep. aga	24	1	23	0
2022-241	001 AEROBIC	034 MICROSCAN			110 110		110 - Lister. mo	22	22	22	100
2022-241	001 AEROBIC	046 MICROSCAN			110 110		210 - Strep. sa.	32	2	30	0
2022-241	001 AEROBIC	046 MICROSCAN			110 110		110 - Lister. mo	32	30	30	100
2022-241	001 AEROBIC	049 VITEK 2			110 110		110 - Lister. mo	40	40	40	100
112 BACTER.-IDENTIFICAT.											
2022-242	001 AEROBIC	032 MICROSCAN			068 068		068 - Escher. co	53	26	52	100
2022-242	001 AEROBIC	032 MICROSCAN			188 188		258 - g -bacilli	53	1	52	0
2022-242	001 AEROBIC	032 MICROSCAN			188 188		188 - Staphy. ep	53	26	52	100
2022-242	001 AEROBIC	034 MICROSCAN			068 068		068 - Escher. co	50	25	50	100
2022-242	001 AEROBIC	034 MICROSCAN			188 188		188 - Staphy. ep	50	25	50	100
2022-242	001 AEROBIC	046 MICROSCAN			068 068		068 - Escher. co	63	33	63	100
2022-242	001 AEROBIC	046 MICROSCAN			188 188		188 - Staphy. ep	63	30	63	100
2022-242	001 AEROBIC	049 VITEK 2			188 188		188 - Staphy. ep	79	39	79	100
2022-242	001 AEROBIC	049 VITEK 2			068 068		068 - Escher. co	79	40	79	100
2022-243	001 AEROBIC	032 MICROSCAN			166 166		166 - Salmon. en	26	22	26	100
2022-243	001 AEROBIC	032 MICROSCAN			166 166		162 - Salmon. sp	26	4	26	100
2022-243	001 AEROBIC	034 MICROSCAN			166 166		166 - Salmon. en	25	22	24	100
2022-243	001 AEROBIC	034 MICROSCAN			166 166		169 - Salmon s B	25	1	24	0
2022-243	001 AEROBIC	034 MICROSCAN			166 166		162 - Salmon. sp	25	2	24	100
2022-243	001 AEROBIC	046 MICROSCAN			166 166		166 - Salmon. en	33	19	33	100
2022-243	001 AEROBIC	046 MICROSCAN			166 166		162 - Salmon. sp	33	14	33	100
2022-243	001 AEROBIC	049 VITEK 2			166 166		166 - Salmon. en	39	4	36	100
2022-243	001 AEROBIC	049 VITEK 2			166 166		162 - Salmon. sp	39	32	36	100
2022-243	001 AEROBIC	049 VITEK 2			166 166		169 - Salmon s B	39	3	36	0
2022-244	001 AEROBIC	032 MICROSCAN			105 105		105 - Klebsi. pn	26	26	26	100
2022-244	001 AEROBIC	034 MICROSCAN			105 105		105 - Klebsi. pn	25	25	25	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY				SUB: 140 BACTERIOLOGY				GRP: 270 BACTERIOLOGY IDENT.			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-244	001 AEROBIC	046 MICROSCAN			105 105		105 - Klebsi. pn	33	33	33	100
2022-244	001 AEROBIC	049 VITEK 2			105 105		104 - Klebsi. oz	40	2	38	0
2022-244	001 AEROBIC	049 VITEK 2			105 105		105 - Klebsi. pn	40	38	38	100
112 BACTER.-IDENTIFICAT.											
2022-245	001 AEROBIC	032 MICROSCAN			190 190		190 - Staphy. sa	26	25	25	100
2022-245	001 AEROBIC	032 MICROSCAN			190 190		188 - Staphy. ep	26	1	25	0
2022-245	001 AEROBIC	034 MICROSCAN			190 190		190 - Staphy. sa	25	25	25	100
2022-245	001 AEROBIC	046 MICROSCAN			190 190		252 - S. xylosus	32	1	31	0
2022-245	001 AEROBIC	046 MICROSCAN			190 190		190 - Staphy. sa	32	31	31	100
2022-245	001 AEROBIC	049 VITEK 2			190 190		190 - Staphy. sa	40	40	40	100
SPE: 50 MICROBIOLOGY											
SUB: 140 BACTERIOLOGY				GRP: 280 BACT. ANTIMIC. SUSC.							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
113 BACT.ANTIM. SUSCEPT.											
2022-244	004 MICRO SCAN	001 AMIKACIN	000 Not apply		001 001		001 - SUSCEPTIB.	42	42	42	100
2022-244	004 MICRO SCAN	003 AMPICILLIN	000 Not apply		004 004		001 - SUSCEPTIB.	32	1	31	0
2022-244	004 MICRO SCAN	003 AMPICILLIN	000 Not apply		004 004		004 - RESISTANT	32	31	31	100
2022-244	004 MICRO SCAN	004 AMPIC/SULB	000 Not apply		001 001		001 - SUSCEPTIB.	21	20	20	100
2022-244	004 MICRO SCAN	004 AMPIC/SULB	000 Not apply		001 001		004 - RESISTANT	21	1	20	0
2022-244	004 MICRO SCAN	007 AZTREONAM	000 Not apply		001 001		001 - SUSCEPTIB.	15	15	15	100
2022-244	004 MICRO SCAN	010 CEFAZOLIN	000 Not apply		001 001		001 - SUSCEPTIB.	56	56	56	100
2022-244	004 MICRO SCAN	019 CEFOXITIN	000 Not apply		001 001		001 - SUSCEPTIB.	10	10	10	100
2022-244	004 MICRO SCAN	020 CEFTAZIDIM	000 Not apply		001 001		001 - SUSCEPTIB.	17	17	17	100
2022-244	004 MICRO SCAN	022 CEFTRIAXON	000 Not apply		001 001		001 - SUSCEPTIB.	13	13	13	100
2022-244	004 MICRO SCAN	029 CIPROFLOXA	000 Not apply		001 001		001 - SUSCEPTIB.	58	58	58	100
2022-244	004 MICRO SCAN	037 GENTAMICIN	000 Not apply		001 001		001 - SUSCEPTIB.	52	52	52	100
2022-244	004 MICRO SCAN	038 IMIPENEM	000 Not apply		001 001		001 - SUSCEPTIB.	27	27	27	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 140 BACTERIOLOGY

GRP: 280 BACT. ANTIMIC. SUSC.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2022-244	004	MICRO SCAN	050	NITROFURAN	000	Not apply	001 001	001 - SUSCEPTIB.	58	58	58	100
2022-244	004	MICRO SCAN	062	TETRACYCLI	000	Not apply	001 001	001 - SUSCEPTIB.	14	14	14	100
2022-244	004	MICRO SCAN	065	TOBRAMYCIN	000	Not apply	001 001	001 - SUSCEPTIB.	54	54	54	100
2022-244	004	MICRO SCAN	066	TRIMETHOPR	000	Not apply	001 001	001 - SUSCEPTIB.	18	18	18	100
2022-244	004	MICRO SCAN	067	TRIME/SULF	000	Not apply	001 001	001 - SUSCEPTIB.	63	63	63	100
2022-244	004	MICRO SCAN	072	CEFEPIME	000	Not apply	001 001	001 - SUSCEPTIB.	29	29	29	100
2022-244	004	MICRO SCAN	073	PIPER/TAZO	000	Not apply	001 001	001 - SUSCEPTIB.	19	19	19	100
2022-244	004	MICRO SCAN	080	LEVOFLOXA.	000	Not apply	001 001	001 - SUSCEPTIB.	46	46	46	100
2022-244	004	MICRO SCAN	096	ERTAPENEM	000	Not apply	001 001	001 - SUSCEPTIB.	17	17	17	100
2022-244	006	VITEK SYS.	001	AMIKACIN	000	Not apply	001 001	001 - SUSCEPTIB.	14	14	14	100
2022-244	006	VITEK SYS.	002	AMOX/CLAVU	000	Not apply	001 001	001 - SUSCEPTIB.	10	10	10	100
2022-244	006	VITEK SYS.	003	AMPICILLIN	000	Not apply	004 004	004 - RESISTANT	19	19	19	100
2022-244	006	VITEK SYS.	004	AMPIC/SULB	000	Not apply	001 001	001 - SUSCEPTIB.	14	14	13	100
2022-244	006	VITEK SYS.	004	AMPIC/SULB	000	Not apply	001 001	001 - SUSCEPTIB.	14	14	13	0
2022-244	006	VITEK SYS.	010	CEFAZOLIN	000	Not apply	001 001	001 - SUSCEPTIB.	24	24	22	100
2022-244	006	VITEK SYS.	010	CEFAZOLIN	000	Not apply	001 001	001 - SUSCEPTIB.	24	24	22	0
2022-244	006	VITEK SYS.	020	CEFTAZIDIM	000	Not apply	001 001	001 - SUSCEPTIB.	12	12	11	100
2022-244	006	VITEK SYS.	020	CEFTAZIDIM	000	Not apply	001 001	001 - SUSCEPTIB.	12	12	11	0
2022-244	006	VITEK SYS.	022	CEFTRIAXON	000	Not apply	001 001	001 - SUSCEPTIB.	16	16	15	100
2022-244	006	VITEK SYS.	022	CEFTRIAXON	000	Not apply	001 001	001 - SUSCEPTIB.	16	16	15	0
2022-244	006	VITEK SYS.	029	CIPROFLOXA	000	Not apply	001 001	001 - SUSCEPTIB.	37	37	36	100
2022-244	006	VITEK SYS.	029	CIPROFLOXA	000	Not apply	001 001	001 - SUSCEPTIB.	37	37	36	0
2022-244	006	VITEK SYS.	037	GENTAMICIN	000	Not apply	001 001	001 - SUSCEPTIB.	27	27	26	100
2022-244	006	VITEK SYS.	037	GENTAMICIN	000	Not apply	001 001	001 - SUSCEPTIB.	27	27	26	0
2022-244	006	VITEK SYS.	038	IMIPENEM	000	Not apply	001 001	001 - SUSCEPTIB.	21	21	20	100
2022-244	006	VITEK SYS.	038	IMIPENEM	000	Not apply	001 001	001 - SUSCEPTIB.	21	21	20	0
2022-244	006	VITEK SYS.	050	NITROFURAN	000	Not apply	001 001	001 - SUSCEPTIB.	41	41	39	100
2022-244	006	VITEK SYS.	050	NITROFURAN	000	Not apply	001 001	001 - SUSCEPTIB.	41	41	39	0
2022-244	006	VITEK SYS.	065	TOBRAMYCIN	000	Not apply	001 001	001 - SUSCEPTIB.	27	27	26	100
2022-244	006	VITEK SYS.	065	TOBRAMYCIN	000	Not apply	001 001	001 - SUSCEPTIB.	27	27	26	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 140 BACTERIOLOGY

GRP: 280 BACT. ANTIMIC. SUSC.

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-244	006 VITEK SYS.	067 TRIME/SULF	000 Not apply		001 001		001 - SUSCEPTIB.	35	35	33	100
2022-244	006 VITEK SYS.	067 TRIME/SULF	000 Not apply		001 001		001 - SUSCEPTIB.	35	35	33	0
2022-244	006 VITEK SYS.	072 CEFEPIME	000 Not apply		001 001		001 - SUSCEPTIB.	26	26	25	100
2022-244	006 VITEK SYS.	072 CEFEPIME	000 Not apply		001 001		001 - SUSCEPTIB.	26	26	25	0
2022-244	006 VITEK SYS.	073 PIPER/TAZO	000 Not apply		001 001		001 - SUSCEPTIB.	19	19	18	100
2022-244	006 VITEK SYS.	073 PIPER/TAZO	000 Not apply		001 001		001 - SUSCEPTIB.	19	19	18	0
2022-244	006 VITEK SYS.	080 LEVOFLOXA.	000 Not apply		001 001		001 - SUSCEPTIB.	15	15	14	100
2022-244	006 VITEK SYS.	080 LEVOFLOXA.	000 Not apply		001 001		001 - SUSCEPTIB.	15	15	14	0
2022-244	006 VITEK SYS.	096 ERTAPENEM	000 Not apply		001 001		001 - SUSCEPTIB.	13	13	12	100
2022-244	006 VITEK SYS.	096 ERTAPENEM	000 Not apply		001 001		001 - SUSCEPTIB.	13	13	12	0
113 BACT.ANTIM. SUSCEPT.											
2022-245	004 MICRO SCAN	029 CIPROFLOXA	000 Not apply		001 001		001 - SUSCEPTIB.	67	67	65	100
2022-245	004 MICRO SCAN	029 CIPROFLOXA	000 Not apply		001 001		001 - SUSCEPTIB.	67	67	65	0
2022-245	004 MICRO SCAN	037 GENTAMICIN	000 Not apply		001 001		001 - SUSCEPTIB.	29	29	27	100
2022-245	004 MICRO SCAN	037 GENTAMICIN	000 Not apply		001 001		001 - SUSCEPTIB.	29	29	27	0
2022-245	004 MICRO SCAN	050 NITROFURAN	000 Not apply		001 001		001 - SUSCEPTIB.	63	63	61	100
2022-245	004 MICRO SCAN	050 NITROFURAN	000 Not apply		001 001		001 - SUSCEPTIB.	63	63	61	0
2022-245	004 MICRO SCAN	053 OXACILLIN	000 Not apply		001 001		004 - RESISTANT	31	4	26	0
2022-245	004 MICRO SCAN	053 OXACILLIN	000 Not apply		001 001		001 - SUSCEPTIB.	31	27	26	100
2022-245	004 MICRO SCAN	053 OXACILLIN	000 Not apply		001 001		001 - SUSCEPTIB.	31	27	26	0
2022-245	004 MICRO SCAN	054 PENICILLIN	000 Not apply		001 001		001 - SUSCEPTIB.	28	25	25	100
2022-245	004 MICRO SCAN	054 PENICILLIN	000 Not apply		001 001		004 - RESISTANT	28	3	25	0
2022-245	004 MICRO SCAN	057 RIFAMPIN	000 Not apply		001 001		001 - SUSCEPTIB.	16	15	14	100
2022-245	004 MICRO SCAN	057 RIFAMPIN	000 Not apply		001 001		001 - SUSCEPTIB.	16	15	14	0
2022-245	004 MICRO SCAN	057 RIFAMPIN	000 Not apply		001 001		004 - RESISTANT	16	1	14	0
2022-245	004 MICRO SCAN	062 TETRACYCLI	000 Not apply		001 001		001 - SUSCEPTIB.	29	29	28	100
2022-245	004 MICRO SCAN	062 TETRACYCLI	000 Not apply		001 001		001 - SUSCEPTIB.	29	29	28	0
2022-245	004 MICRO SCAN	067 TRIME/SULF	000 Not apply		001 001		001 - SUSCEPTIB.	80	80	78	100
2022-245	004 MICRO SCAN	067 TRIME/SULF	000 Not apply		001 001		001 - SUSCEPTIB.	80	80	78	0
2022-245	004 MICRO SCAN	068 VANCOMYCIN	000 Not apply		001 001		001 - SUSCEPTIB.	50	50	48	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY													SUB: 140 BACTERIOLOGY			GRP: 280 BACT. ANTIMIC. SUSC.		
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score				
2022-245	004	MICRO SCAN	068	VANCOMYCIN	000	Not apply		001 001		001 - SUSCEPTIB.	50	50	48	0				
2022-245	004	MICRO SCAN	080	LEVOFLOXA.	000	Not apply		001 001		001 - SUSCEPTIB.	37	37	36	100				
2022-245	004	MICRO SCAN	080	LEVOFLOXA.	000	Not apply		001 001		001 - SUSCEPTIB.	37	37	36	0				
2022-245	004	MICRO SCAN	086	LINEZOLID	000	Not apply		001 001		001 - SUSCEPTIB.	41	41	40	100				
2022-245	004	MICRO SCAN	086	LINEZOLID	000	Not apply		001 001		001 - SUSCEPTIB.	41	41	40	0				
2022-245	004	MICRO SCAN	097	DAPTOMYCIN	000	Not apply		001 001		001 - SUSCEPTIB.	17	17	16	100				
2022-245	004	MICRO SCAN	097	DAPTOMYCIN	000	Not apply		001 001		001 - SUSCEPTIB.	17	17	16	0				
2022-245	006	VITEK SYS.	029	CIPROFLOXA	000	Not apply		001 001		001 - SUSCEPTIB.	31	31	31	100				
2022-245	006	VITEK SYS.	037	GENTAMICIN	000	Not apply		001 001		001 - SUSCEPTIB.	13	13	13	100				
2022-245	006	VITEK SYS.	050	NITROFURAN	000	Not apply		001 001		001 - SUSCEPTIB.	38	38	38	100				
2022-245	006	VITEK SYS.	053	OXACILLIN	000	Not apply		004 004		004 - RESISTANT	16	15	15	100				
2022-245	006	VITEK SYS.	053	OXACILLIN	000	Not apply		004 004		001 - SUSCEPTIB.	16	1	15	0				
2022-245	006	VITEK SYS.	062	TETRACYCLI	000	Not apply		001 001		001 - SUSCEPTIB.	27	27	27	100				
2022-245	006	VITEK SYS.	067	TRIME/SULF	000	Not apply		001 001		001 - SUSCEPTIB.	41	41	41	100				
2022-245	006	VITEK SYS.	068	VANCOMYCIN	000	Not apply		001 001		001 - SUSCEPTIB.	38	38	38	100				
2022-245	006	VITEK SYS.	080	LEVOFLOXA.	000	Not apply		001 001		001 - SUSCEPTIB.	17	17	17	100				
2022-245	006	VITEK SYS.	086	LINEZOLID	000	Not apply		001 001		001 - SUSCEPTIB.	31	31	31	100				

SPE: 50 MICROBIOLOGY													SUB: 170 PARASITOLOGY			GRP: 350 ID OF PARASITES		
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score				
120 IDENT OF PARASITES																		
2022-311	003	E. coli	002	CYSTS				002 004		002 - FEW	66	47	59	100				
2022-311	003	E. coli	002	CYSTS				002 004		003 - MODERATE	66	12	59	100				
2022-311	003	E. coli	002	CYSTS				002 004		006 - PAR NOT RE	66	7	59	0				
2022-311	015	Trichuris	003	OVA OR EGG				002 004		002 - FEW	66	46	66	100				
2022-311	015	Trichuris	003	OVA OR EGG				002 004		004 - MANY	66	1	66	100				

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 170 PARASITOLOGY

GRP: 350 ID OF PARASITES

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-311	015	Trichuris	003	OVA OR EGG	002	004	003 - MODERATE	66	19	66	100
2022-311	016	Ascaris l.	003	OVA OR EGG	002	004	003 - MODERATE	66	36	66	100
2022-311	016	Ascaris l.	003	OVA OR EGG	002	004	002 - FEW	66	8	66	100
2022-311	016	Ascaris l.	003	OVA OR EGG	002	004	004 - MANY	66	22	66	100
2022-311	017	Hookworm	003	OVA OR EGG	001	001	003 - MODERATE	48	7	48	100
2022-311	017	Hookworm	003	OVA OR EGG	001	001	002 - FEW	48	41	48	100
2022-311	024	Hymenolep.	003	OVA OR EGG			002 - FEW	10	10	0	0
120 IDENT OF PARASITES											
2022-312	001	E. histoly	002	CYSTS	001	001	004 - MANY	18	1	18	100
2022-312	001	E. histoly	002	CYSTS	001	001	002 - FEW	18	16	18	100
2022-312	001	E. histoly	002	CYSTS	001	001	003 - MODERATE	18	1	18	100
2022-312	003	E. coli	002	CYSTS	001	001	003 - MODERATE	21	1	21	100
2022-312	003	E. coli	002	CYSTS	001	001	002 - FEW	21	20	21	100
2022-312	004	Endo. nana	002	CYSTS	001	001	004 - MANY	13	1	13	100
2022-312	004	Endo. nana	002	CYSTS	001	001	003 - MODERATE	13	5	13	100
2022-312	004	Endo. nana	002	CYSTS	001	001	002 - FEW	13	7	13	100
2022-312	009	Giardia l.	002	CYSTS	002	004	004 - MANY	66	14	66	100
2022-312	009	Giardia l.	002	CYSTS	002	004	003 - MODERATE	66	33	66	100
2022-312	009	Giardia l.	002	CYSTS	002	004	002 - FEW	66	19	66	100
2022-312	036	Blastocys.	002	CYSTS	001	001	004 - MANY	36	2	36	100
2022-312	036	Blastocys.	002	CYSTS	001	001	003 - MODERATE	36	10	36	100
2022-312	036	Blastocys.	002	CYSTS	001	001	002 - FEW	36	24	36	100
2022-313	003	E. coli	002	CYSTS	001	001	002 - FEW	10	10	10	100
2022-313	009	Giardia l.	002	CYSTS	001	001	004 - MANY	59	1	59	100
2022-313	009	Giardia l.	002	CYSTS	001	001	002 - FEW	59	49	59	100
2022-313	009	Giardia l.	002	CYSTS	001	001	003 - MODERATE	59	9	59	100
2022-313	015	Trichuris	003	OVA OR EGG	002	004	004 - MANY	66	3	64	100
2022-313	015	Trichuris	003	OVA OR EGG	002	004	006 - PAR NOT RE	66	2	64	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 170 PARASITOLOGY

GRP: 350 ID OF PARASITES

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-313	015	Trichuris	003	OVA OR EGG	002	004	003 - MODERATE	66	26	64	100
2022-313	015	Trichuris	003	OVA OR EGG	002	004	002 - FEW	66	35	64	100
2022-313	016	Ascaris l.	003	OVA OR EGG	002	004	004 - MANY	66	7	66	100
2022-313	016	Ascaris l.	003	OVA OR EGG	002	004	003 - MODERATE	66	33	66	100
2022-313	016	Ascaris l.	003	OVA OR EGG	002	004	002 - FEW	66	26	66	100
2022-313	017	Hookworm	003	OVA OR EGG	002	004	003 - MODERATE	66	21	64	100
2022-313	017	Hookworm	003	OVA OR EGG	002	004	002 - FEW	66	40	64	100
2022-313	017	Hookworm	003	OVA OR EGG	002	004	004 - MANY	66	3	64	100
2022-313	017	Hookworm	003	OVA OR EGG	002	004	006 - PAR NOT RE	66	2	64	0
120 IDENT OF PARASITES											
2022-314	027	Diphyllob.	003	OVA OR EGG	001	001	003 - MODERATE	28	9	28	100
2022-314	027	Diphyllob.	003	OVA OR EGG	001	001	002 - FEW	28	15	28	100
2022-314	027	Diphyllob.	003	OVA OR EGG	001	001	004 - MANY	28	4	28	100
2022-314	033	Paragonim.	003	OVA OR EGG	001	001	003 - MODERATE	46	23	46	100
2022-314	033	Paragonim.	003	OVA OR EGG	001	001	002 - FEW	46	16	46	100
2022-314	033	Paragonim.	003	OVA OR EGG	001	001	004 - MANY	46	7	46	100
2022-315	002	E. hartman	002	CYSTS	005	005	002 - FEW	66	2	63	100
2022-315	002	E. hartman	002	CYSTS	005	005	005 - NOT APPLY	66	61	63	100
2022-315	002	E. hartman	002	CYSTS	005	005	006 - PAR NOT RE	66	3	63	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY				SUB: 170 PARASITOLOGY				GRP: 360 PRES/ABS OF PARASITE			
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
121 PRESENCE OR ABSENCE											
2022-311				002 002	002 002		002 - Presence	38	38	38	100
2022-312				002 002	002 002		001 - Absence	38	4	34	0
2022-312				002 002	002 002		002 - Presence	38	34	34	100
2022-313				002 002	002 002		002 - Presence	38	38	38	100
2022-314				002 002	002 002		001 - Absence	34	1	33	0
2022-314				002 002	002 002		002 - Presence	34	33	33	100
2022-315				002 002	002 002		002 - Presence	34	34	34	100
176 INFLUENZA A&B QUALI											
2022-251	001 INFLU. A	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	97	97	100
2022-251	001 INFLU. A	004 Sekisui Os		001 001	001 001		002 - POSITIVE	136	1	135	0
2022-251	001 INFLU. A	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	136	135	135	100
2022-251	001 INFLU. A	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-251	001 INFLU. A	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-251	001 INFLU. A	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-251	001 INFLU. A	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-251	001 INFLU. A	012 BIOSIG A+B		001 001	001 001		002 - POSITIVE	260	2	258	0

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 180 Virology

GRP: 400 Influenza A & B

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-251	001 INFLU. A	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	260	258	258	100
2022-251	002 INFLU. B	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	97	97	100
2022-251	002 INFLU. B	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	138	138	138	100
2022-251	002 INFLU. B	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-251	002 INFLU. B	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-251	002 INFLU. B	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-251	002 INFLU. B	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-251	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		002 - POSITIVE	260	1	259	0
2022-251	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	260	259	259	100
176	INFLUENZA A&B QUALI										
2022-252	001 INFLU. A	003 Sofia CLIA		002 002	002 002		002 - POSITIVE	97	97	97	100
2022-252	001 INFLU. A	004 Sekisui Os		002 002	002 002		002 - POSITIVE	137	136	136	100
2022-252	001 INFLU. A	004 Sekisui Os		002 002	002 002		001 - NEGATIVE	137	1	136	0
2022-252	001 INFLU. A	006 Quidel Flu		002 002	002 002		002 - POSITIVE	50	50	50	100
2022-252	001 INFLU. A	007 BD Veritor		002 002	002 002		002 - POSITIVE	24	24	24	100
2022-252	001 INFLU. A	008 Remel x/p		002 002	002 002		002 - POSITIVE	19	19	19	100
2022-252	001 INFLU. A	010 OraSure		002 002	002 002		002 - POSITIVE	132	132	132	100
2022-252	001 INFLU. A	012 BIOSIG A+B		002 002	002 002		002 - POSITIVE	260	260	260	100
2022-252	002 INFLU. B	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	97	97	100
2022-252	002 INFLU. B	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	136	136	136	100
2022-252	002 INFLU. B	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-252	002 INFLU. B	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-252	002 INFLU. B	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-252	002 INFLU. B	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-252	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	260	260	260	100
2022-253	001 INFLU. A	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	97	97	100
2022-253	001 INFLU. A	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	137	137	137	100
2022-253	001 INFLU. A	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 180 Virology

GRP: 400 Influenza A & B

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2022-253	001 INFLU. A	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-253	001 INFLU. A	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-253	001 INFLU. A	010 OraSure		001 001	001 001		001 - NEGATIVE	133	132	132	100
2022-253	001 INFLU. A	010 OraSure		001 001	001 001		002 - POSITIVE	133	1	132	0
2022-253	001 INFLU. A	012 BIOSIG A+B		001 001	001 001		002 - POSITIVE	261	1	260	0
2022-253	001 INFLU. A	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	261	260	260	100
2022-253	002 INFLU. B	003 Sofia CLIA		002 002	002 002		002 - POSITIVE	96	96	96	100
2022-253	002 INFLU. B	004 Sekisui Os		002 002	002 002		002 - POSITIVE	137	137	137	100
2022-253	002 INFLU. B	006 Quidel Flu		002 002	002 002		002 - POSITIVE	50	50	50	100
2022-253	002 INFLU. B	007 BD Veritor		002 002	002 002		002 - POSITIVE	24	24	24	100
2022-253	002 INFLU. B	008 Remel x/p		002 002	002 002		002 - POSITIVE	19	19	19	100
2022-253	002 INFLU. B	010 OraSure		002 002	002 002		002 - POSITIVE	131	131	131	100
2022-253	002 INFLU. B	012 BIOSIG A+B		002 002	002 002		002 - POSITIVE	259	259	259	100
176	INFLUENZA A&B QUALI										
2022-254	001 INFLU. A	003 Sofia CLIA		001 001	001 001		002 - POSITIVE	97	2	95	0
2022-254	001 INFLU. A	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	95	95	100
2022-254	001 INFLU. A	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	136	136	136	100
2022-254	001 INFLU. A	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-254	001 INFLU. A	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-254	001 INFLU. A	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-254	001 INFLU. A	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-254	001 INFLU. A	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	259	259	259	100
2022-254	002 INFLU. B	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	97	97	97	100
2022-254	002 INFLU. B	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	136	136	136	100
2022-254	002 INFLU. B	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-254	002 INFLU. B	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-254	002 INFLU. B	008 Remel x/p		001 001	001 001		001 - NEGATIVE	19	19	19	100
2022-254	002 INFLU. B	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-254	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	260	260	260	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY

SUB: 180 Virology

GRP: 400 Influenza A & B

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
176 INFLUENZA A&B QUALI											
2022-255	001 INFLU. A	003 Sofia CLIA		002 002	002 002		002 - POSITIVE	97	97	97	100
2022-255	001 INFLU. A	004 Sekisui Os		002 002	002 002		001 - NEGATIVE	137	11	126	0
2022-255	001 INFLU. A	004 Sekisui Os		002 002	002 002		002 - POSITIVE	137	126	126	100
2022-255	001 INFLU. A	006 Quidel Flu		002 002	002 002		001 - NEGATIVE	50	2	48	0
2022-255	001 INFLU. A	006 Quidel Flu		002 002	002 002		002 - POSITIVE	50	48	48	100
2022-255	001 INFLU. A	007 BD Veritor		002 002	002 002		002 - POSITIVE	24	24	24	100
2022-255	001 INFLU. A	008 Remel x/p			002 002		002 - POSITIVE	20	13	13	100
2022-255	001 INFLU. A	008 Remel x/p			002 002		001 - NEGATIVE	20	7	13	0
2022-255	001 INFLU. A	010 OraSure		002 002	002 002		001 - NEGATIVE	132	26	106	0
2022-255	001 INFLU. A	010 OraSure		002 002	002 002		002 - POSITIVE	132	106	106	100
2022-255	001 INFLU. A	012 BIOSIG A+B		002 002	002 002		002 - POSITIVE	260	227	227	100
2022-255	001 INFLU. A	012 BIOSIG A+B		002 002	002 002		001 - NEGATIVE	260	33	227	0
2022-255	002 INFLU. B	003 Sofia CLIA		001 001	001 001		001 - NEGATIVE	98	98	98	100
2022-255	002 INFLU. B	004 Sekisui Os		001 001	001 001		001 - NEGATIVE	136	136	136	100
2022-255	002 INFLU. B	006 Quidel Flu		001 001	001 001		001 - NEGATIVE	50	50	50	100
2022-255	002 INFLU. B	007 BD Veritor		001 001	001 001		001 - NEGATIVE	24	24	24	100
2022-255	002 INFLU. B	008 Remel x/p		001 001	001 001		001 - NEGATIVE	18	18	18	100
2022-255	002 INFLU. B	010 OraSure		001 001	001 001		001 - NEGATIVE	132	132	132	100
2022-255	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		002 - POSITIVE	260	2	258	0
2022-255	002 INFLU. B	012 BIOSIG A+B		001 001	001 001		001 - NEGATIVE	260	258	258	100

Participant Summary

MONTH 4 OF YEAR 2022

SPE: 50 MICROBIOLOGY		SUB: 180 Virology				GRP: 450 RSV Syncytial Virus						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
555 Resp Syncytial Virus												
2022-251	001	ALERE ABBO		001	001	001	001	001 - Neg	28	28	28	100
2022-251	002	SOFIA RSV		001	001	001	001	001 - Neg	26	26	26	100
2022-252	001	ALERE ABBO		001	001	001	001	001 - Neg	28	28	28	100
2022-252	002	SOFIA RSV		001	001	001	001	001 - Neg	26	26	26	100
2022-253	001	ALERE ABBO		001	001	001	001	001 - Neg	28	28	28	100
2022-253	002	SOFIA RSV		001	001	001	001	001 - Neg	26	26	26	100
2022-254	001	ALERE ABBO		002	002	002	002	002 - Pos	28	28	28	100
2022-254	002	SOFIA RSV		002	002	002	002	002 - Pos	26	26	26	100
2022-255	001	ALERE ABBO		001	001	001	001	001 - Neg	28	28	28	100
2022-255	002	SOFIA RSV		001	001	001	001	001 - Neg	26	26	26	100